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When the m2 muscarinic receptor was expressed in Chinese hamster ovary cells
the EC50 of adenylyl cyclase inhibition decreased but the extent remained constant with
increasing receptor levels. The EC50 for phosphatidylinositol metabolism stimulation
was unaffected but its extent increased with increasing receptor levels. The ternary
complex model was expanded to explicitly include composite G protein activation steps
from receptorG protein and agonistreceptorG protein complexes. This expanded
model explained these effects, partial agonism that disappeared at high receptor level, and
negative antagonism.
The model explained the results observed with the site-directed mutant Y403F, a
conserved residue in the sixth transmembrane helix, and resolved apparently conflicting
results seen with the homologous mutation in the m3 muscarinic receptor. In the m3
subtype the mutation resulted in decreased agonist affinity and decreased functional
activity. In the m2 subtype agonist affinity was more affected but functional activity was
wild-type-like except for pilocarpine, where the functional activity was reduced in one
assay and eliminated in another. These effects observed in both subtypes were explained
by changes in the ratio of high affinity to low affinity agonist equilibrium constants thatincreased in the m2 subtype but decreased with pilocarpine in the m2 and for comparable 
agonists in the m3 subtype. 
Conserved aspartate residues in the second and third transmembrane domains 
were mutated individually and in pairs to asparagine. D69N eliminated high and 
preserved low affmity agonist binding and altered agonist-specific functional activation; 
some of these effects were observed with D69.97N. D97N had a small effect on agonist 
binding and functional activity. Double mutant cycles indicate that D69N and D97N 
mutations are additive but D103N-containing double mutants are not. D103N had a 
dramatic effect on expression and ligand binding. D97.103N double mutation eliminated 
functional activity at saturating agonist concentrations at receptor expression levels at 
which full wild-type-like functional activity was observed in D97N. Results from 
D97.103N suggest that D97 and D103 have separate noncooperative roles in ligand 
binding. Thermal inactivation studies suggest that these mutants have at most a small 
effect on receptor structure. © Copyright by Walter Kevin Vogel
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Chapter 1 
Introduction 
History of muscarinic acetylcholine receptor discovery and
background on its action 
Eighteenth century visitors to the Koryak tribe in northeastern Siberia reported 
tribe members being, "subject to various visions, terrifying or felicitous...owing to 
which some jump, some dance, others cry and suffer great terrors, while some deem a 
small crack to be as wide as a door, and a tub of water as deep as the sea."1 This was the 
result of eating (or drinking the urine of someone who has) the fly agaric Amanita 
muscaria, the white-spotted red mushroom sometimes found in the illustrations of 
children's fairy-tales. 
Accounts like these led to studies in 1869 by Schmiedeberg and Koppe (2) who 
showed that extracts from Amanita muscaria could slow, and high concentrations stop 
frog heart beat. They produced an enriched preparation of the active alkaloid and called it 
muscarine (Figure 1.1). They further showed that muscarinic effects on the heart were 
similar to vagal stimulation of the heart and that atropine (Atropa belladonna) blocked 
vagal stimulation. 
Similar work on the effects of curare (Chondrodendron tomentosum) by Claude 
Bernard and later on nicotine (Nicotiana tabacum) by Langley (3) led to the classification 
of acetylcholine effects as either being muscarinic or nicotinic by Dale (4). Muscarinic 
'from the account of Stephen Krasheninnikov, published 1755, and translated in Wasson R. G. (1) 2 
Figure 1.1 Compounds derived from Amanita muscaria 
effects were blocked by atropine and nicotinic effects were nicotine-like acetylcholine 
effects not blocked by atropine. Loewi first suggested that acetylcholine acted as a 
chemical messenger. In 1921 he showed that a substance in frog hearts he called 
vagusstoff transferred from one heart would inhibit the beating of a second (5). Loewi 
and Navaaratil later speculated that the substance was acetylcholine (6) and showed that 
physostigmine (Physostigma venenosa), an inhibitor of the enzyme that breaks down 
acetylcholine, sensitized the heart to vagusstoff (7). Dale and Dudley isolated 
acetylcholine from tissue (8) in 1929 proving that it is a natural constituent (for historical 
reviews see Burgen (9, 10) and Whittaker (11)). Henry Dale and Otto Loewi shared the 
Nobel Prize in 1936 for their work on acetylcholine. 
Agonist effects 
Muscarinic agonists (Figure 1.2) have effects on the heart, smooth muscle, 
exocrine glands, eye, and the central nervous system. They slow the rate and decrease the 
force of contraction of the heart and result in vasodilatation, the combined effect of which 
is the probable origin of the toxic effect of Amanita muscaria when consumed in excess. 
The hallucinogenic effect is probably due to muscimol and ibotenic acid (12), which 
activate GABAA and metabotropic glutamate receptors, respectively, rather than 
muscarine itself (Figure 1.1). Muscarinic agonists cause the smooth muscle of the 
bronchia to contract and increase bronchial secretions; the combined effect can interfere 3 
with breathing, severely. Contraction of smooth muscle in the bladder and increased 
peristaltic action in the gut, which can result in sharp abdominal pain, excess sweating, 
lacrimation, and salivation, are additional side-effects of muscarinic agonists limiting 
their potential as pharmaceuticals. An exception is the use of pilocarpine (Pilocarpus 
jaborandi) to treat glaucoma in the form of eye drops, which reduces the intraocular 
pressure by promoting outflow of the aqueous humor. Muscarinic agonists that can 
cross the bloodbrain barrier, such as arecoline, have the ability to improve short-term 
memory (13). 
Antagonist effects 
Muscarinic antagonists have proved to be more useful as pharmaceuticals than 
agonists in measured amounts and no less deadly if taken in greater quantities. The 
berries of Atropa belladonna when squeezed into the eye cause the pupils to dilate 
imparting the so-called doe-eyed beauty look to Renaissance women, and hence the 
name belladonna; this however, would have resulted in blurry vision for these beautiful 
women. The same berry ingested would kill, a use that was not ignored, giving us the 
genus name Atopa after the oldest of the three Fates in Greek mythology, who cut the 
thread of life. In the current pharmacopoeia atropine (or in optically pure form 
()hyoscyamine) is effective as an antispasmodic in relaxing smooth muscle in the gut. 
Other effects include an increase in the heart rate and decrease in exocrine secretions. 
Scopolamine (Hyoscyamus niger) is used as an antiemetic to prevent motion sickness. 
Ipratropium, an atropine derivative with a quaternary amine so that it does not pass the 
bloodbrain barrier, is inhaled by asthma sufferers for its bronchodilative effect. The 
original version of this therapy involved the smoking of herbal cigarettes containing 
jimson weed (Datura stamonium) produced by the Spanish Cigarette Company (12). 
Antagonist effects in the central nervous system include an increase in body temperature, 
loss of short-term memory, delirium, sedation, and hallucinations. Some of these effects 4 
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Figure 1.2 Muscarinic agonists 
were sought for military purposes and found in 3-quinuclidinyl benzilate, known as 
agent BZ to the military and referred to here as QNB. This incapacitating agent's effects 
are stronger than atropine and last longer while being less deadly (14). 
G protein coupling discovery and action 
The general mechanism of muscarinic receptor action was not understood except 
in parallel with other receptors that appeared to have opposing effects. In the 1950s Earl 
Sutherland's group discovered that the hormones epinephrine and glucagon acted via a 5 
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Figure 1.3 Muscarinic antagonists 6 
second messenger cAMP (15) and that acetylcholine acted in the heart to decrease cAMP 
levels (16). Earl Sutherland received the Nobel prize in 1971 for working out this second 
messenger system. The mechanism by which hormone binding at cell surface receptors 
affects adenylyl cyclase activity via G proteins was worked out primarily in the 
laboratory of Martin Rodbell in the late 1960s and early 1970s. Birnbaumer and Rodbell 
(17) observed that several different receptors stimulated adenylyl cyclase by a common 
mechanism and postulated that a regulatory element existed between the hormone 
binding receptor and the adenylyl cyclase effector (18). Guanine nucleotides were found 
to affect the affinity of glucagon for its receptor (19) and to be essential for adenylyl 
cyclase activity (20) suggesting that the regulatory element bound guanine nucleotide. 
Subsequent results indicated that stimulation and inhibition of adenylyl cyclase occurred 
via different guanine nucleotide binding proteins (21) that were later identified as the G 
proteins Gs and Gi. 
Rodbell's group had shown by the early 1970s that signal transduction elements 
that bind guanine nucleotides existed and were capable of affecting both receptors and 
effectors but they did not know what they were or how they worked. Casell and Se linger 
(22) observed that 0-adrenergic agonists stimulated a GTPase and proposed that the 
hydrolysis of GTP was responsible for suspending the signal, and Pfeuffer (23) first 
identified a G protein by photoaffmity labeling of detergent extracts of avian erythrocytes 
and showed that the partially-purified detergent-solubilized protein resolved from 
receptor and adenylyl cyclase reconstituted adenylyl cyclase activity. Parallel experiments 
in Alfred Gilman's laboratory using a mutant leukemia cell line devoid of adenylyl 
cyclase activity but containing P-adrenergic receptors (24) identified a heat stable 
component that was necessary for adenylyl cyclase activity (25) and later purified this 
component (26). This protein was later termed G. Subsequently Gi (27), which 
inhibited adenylyl cyclase, and Go (28, 29), which had no obvious function at the time, 7 
were also purified. The heterotrimeric nature of G proteins became evident as a 
consequence of purification (see Gilman review (30)). Rodbell and Gilman received the 
Nobel prize in 1994 for their work on the discovery of G proteins and their role in signal 
transduction. 
Receptor classification 
Muscarinic acetylcholine receptors have been classified into three subtypes 
pharmacologically and five genetically. The three pharmacological subtypes, M1 
(neural), M2 (cardiac), and M3 (glandular), are distinguishable by their selective binding 
of pirenzepine (31) (M1 selective) and AF-DX 116 (32) and gallamine (33) (M2 
selective) , and p-fluorohexahydrosiladifenidol (34) (M3 selective). Five vertebrate 
muscarinic receptor genes are known and are designated subtypes mlm5 (35-43), and 
a sixth gene from Drosophila melanogaster is designated mdl (44, 45). mRNA blotting 
and cDNA cloning experiments on mammalian tissue indicate that in the brain all five 
subtypes are present (36, 38, 39, 43, 46-51), in the heart m2 is present (35, 37, 38, 47) 
while in chick heart m2 predominates followed by m4 and m3 (additionally m3 is a 
developmentally regulated and present in higher concentrations in early developmental 
stages) (49, 52, 53), in glandular tissue ml and m3 and in smooth muscle m2 and m3 
are present (47), and in a human melanoma cell line only m5 is present (54). 
Muscarinic receptors are members of a diverse homologous group of membrane 
proteins that are distinguished structurally by seven hydrophobic domains that are 
assigned as transmembrane a-helices and functionally by their ability to interact with G 
proteins. G protein-coupled receptors are responsible for our sense of smell, sight, and 
taste, they bind neuropeptides, biogenic amines, and glycoprotein hormones; additional 
receptors (orphan receptors in Table 1.1) have no known purpose. Their common 
purpose is transmembrane communication. Distinct members of the superfamily of G 
protein-coupled receptors that have been identified by DNA cloning are listed in Table 8 
Table 1.1 Molecularly identified G protein-coupled receptors 
Family I: Rhodopsin-like 
Amine binding 
adrenergic receptors (10)a
 
dopamine receptors (13)
 
histamine receptors (2)
 
5-hydroxytryptamine receptors (12)
 
muscarinic acetylcholine receptors (6)
 
octopamine receptor
 
Sensory 
olfactory receptors (48+) 
gustatory receptors (8) 
rhodopsins and opsins 
rhodopsin and red, green, and blue opsin in 
humans 
rhodopsin and red, green, blue, violet, and 
pineal opsin in chicken 
Peptide binding 
angiotensin receptors (4) 
neuromedin B receptor 
gastrin-releasing peptide receptor 
bombesin receptors (2) 
neuropeptide Y receptors (8) 
opioid receptors (4) 
somatostatin receptors (5) 
neurokinin receptors (4) 
platelet activating factor receptor 
galanin receptor 
vasopressin receptors (3) 
oxytocin receptor 
thrombin receptor 
proteinase activated receptor 
bradykinin receptors (2) 
orthinthokinin receptor 
endothelin receptors (3) 
complement anaphylatoxin chemotactic 
receptors (2) 
fMet-Leu-Phe receptor and related receptors (3) 
leukotriene B4 receptor 
CXC chemokine receptors (4)
 
Duffy antigen (DARC)
 
CC chemokine receptors (5)
 
macrophage inflammatory protein-la
 
chemokine receptor 
D6 chemokine receptor 
STRL33 chemokine receptor 
cholecystokinin / gastrin receptors (2) 
follicle-stimulating hormone receptor 
lutropin-choriogonadotropic hormone receptor 
thyrotropin receptor 
probable glycoprotein hormone receptor 
gonadotropin-releasing hormone receptor 
thyrotropin-releasing hormone receptor 
growth hormone secretalogue receptor 
prostanoids receptors (8) 
Other molecules 
adenosine receptors (4)
 
purinoceptors (5)
 
cannabinoids receptors (4)
 
melanocortins receptors (3)
 
adrenocorticotropic hormone receptor
 
melanocyte-stimulating hormone receptor
 
neurotensin receptors (2)
 
melanotonin receptors (4)
 
orphan receptors (51)
 
viral receptors (12)
 
Family II: Secretin-like 
calcitonin receptor 
calcitonin gene-related peptide 1 receptor 
corticotropin releasing factor receptors (2) 
diuretic hormone receptor 
gastric inhibitory peptide receptor 
glucagon receptor 
glucagon-like peptide 1 receptor 
growth hormone-releasing hormone receptor 
parathyroid hormone receptor 
pituitary adenylyl cyclase activating peptide I 
receptor 
secretin receptor 
vasoactive intestinal peptide receptors (2) 
orphan receptors (4) 
Family III: Metabotropic glutamate 
and calcium receptors 
metabotropic glutamate receptors (9) 
extracellular calcium-sensing receptor 
Family IV: cAMP receptors 
(slime mold) 
cAMP receptors from Dictyostelium 
discoideum (3) 
Family V: Pheromone receptors 
(fungal) 
pheromone receptors (8) 
avalues in parentheses are the number of distinct molecular species represented by the entry 9 
1.1. Approximately 800 protein sequences of G protein-coupled receptors have been 
identified representing in excess of 300 distinct molecular entities. It is estimated that 
approximately 1000 of the genome's 100,000 genes encode G protein-coupled receptors 
(55). The primary sequence of bovine rhodopsin was the first of these structures 
available (56, 57) and its structural similarity to bacteriorhodopsin was immediately 
evident and applied to structural models of rhodopsin based on the seven transmembrane 
a-helices of bacteriorhodopsin (58). However, there is no sequence homology between 
these proteins, and bacteriorhodopsin unlike rhodopsin is an ion channel. While primary 
structures of the four human visual pigments, rhodopsin (59) and red, green, and blue 
opsins (60), indicated a close phylogenetic relationship it was not until the primary 
structure of13-adrenergic receptor became available (61) that it was recognized that the 
entire class of G protein-coupled receptors might share a similar related structure. 
Sequence alignments reveal that the majority of the homology resides in the seven 
hydrophobic transmembrane domains (62-64). G protein-coupled receptors have been 
divided into five phylogenetic families (Table 1.1) (65)2. 
2A large amount of information on G protein-coupled receptors resides in specialized secondary 
databases that have the results of primary database searches, sequence alignments, structure 
modeling tools, databases of site-directed mutants and their effects. The following is a list of the 
publicly available secondary databases relevant to reasearch on G protein-coupled receptors: 
GPCRDB: Information system for G  http://swift-embl-heidelberg.de/7tm 
protein-coupled receptors 
GCRDb: The G protein-coupled receptor  http://receptor.mgh.harvard.edu/ 
database (65)  GCRDBHOME.html 
ORDB: Olfactory database  http://senselab.med.yale.edu/ordb 
Mutation database at NIH  http://mgddkl.niddk.nih.gov:8000/ 
GPCR.html 
ExPASy: The swiss-model 7TM  http://www.espasy.ch/cgi-bin/ 
ProMod-GPCR.pl 
GRAP Mutant database at Troms0,  http://www-grap.fagmed.uit.no/GRAP/ 
Norway (66)  homepage.html 10 
Structure of G protein-coupled receptors 
Atomic resolution structural information on G protein-coupled receptors is 
unavailable and low-resolution projection structures of G protein-coupled rhodopsin 
have only recently reached a level of refinement that allows a tentative model of the 
transmembrane helices to be proposed (67). This 6 A frog rhodopsin projection structure 
suggests that the seven transmembrane helices are packed into a rough circle with helix 4 
and especially helix 1 pushed toward the outside. Helices 1, 2, 3, and 5 are tilted while 4, 
6, and 7 are perpendicular to the plane of the membrane. The putative helices are 
amphipathic with helices 1 and 4 being the most hydrophobic and helix 7 the least. 
Helix 3 is amphipathic only near the extracellular end consistent with projection 
structures. Helices 4, 5, 6, and 7 have conserved prolines suggesting that they are bent or 
have a degree conformational flexibility. The cluster of helices are bundled funnel-like, 
wider at the intradiscal (extracellular homologous) and narrower at the cytoplasmic face 
with helix 3 tilted toward the center of the circle of helices on the cytoplasmic face. See 
Baldwin (68) for a review of the helix arrangement based on the then available 9 A 
bovine rhodopsin projection structure (69). 
The relevance of this structural information to other members of the G protein-
coupled receptor family is unclear. The requirements for the incorporation of visual 
pigment 11-cis-retinal and its isomerization may be particular to rhodopsin. The core 
structural requirements of G protein-coupled receptors are not well enough understood to 
allow rhodopsin to be considered a reliable model for other G protein-coupled receptors. 
Indeed, the funnel-like arrangement of the helices of rhodopsin might be to 
accommodate the relatively large retinal; acetylcholine could be accommodated by more 
narrowly bundled helices in the muscarinic receptor. In the absence of high-resolution 
structures of G protein-coupled receptors, most insights into structure and function have 
been inferred from chemical modification and site-directed mutagenesis experiments. 11 
Hydropathicity analysis of the primary sequence suggests that muscarinic 
receptors cross the cell membrane seven times (35, 37). The receptor is oriented in the 
cell membrane with the amino-terminal extracellular and the carboxyl-terminal 
intracellular. Two highly conserved motifs that could conceivably interact are found at 
the intracellular ends of helices 2 and 3. The aspartate at the bottom of helix 2 (D69 in the 
m2 muscarinic receptor) is conserved with a few exceptions in the rhodopsin-like family 
of G protein-coupled receptors (Table 1.1) and is surrounded by other residues that are 
highly conserved or have a restricted variability (Figure 1.4). At the intracellular end of 
helix 3 there is a patch of residues with restricted variability followed by the conserved 
sequence DRY. Evidence for the close proximity of the helix 2 aspartate and a conserved 
asparagine in helix 7 (N436 in m2 muscarinic receptor), in the conserved NPXXY 
motif, comes from the gonadotropin-releasing hormone receptor where these residues 
are switched. The reciprocal double mutation that restored the typical arrangement of 
aspartate in helix 2 and asparagine in helix 7 restored high affmity agonist and antagonist 
binding lost in the single helix 2 mutation (70). Similar experiments in the 
5-hydroxytryptamine2A receptor showed that high affinity agonist binding and functional 
activity lost in the single were restored in the reciprocal double mutant (71) suggesting 
that this might be a general feature of the rhodopsin-like G protein-coupled receptors. At 
the extracellular end of helix 3 and the extracellular loop between helices 4 and 5 is a pair 
of highly conserved cysteine residues. An aspartate in the middle of helix 3 (D103 in m2 
muscarinic receptor) is conserved among receptors that bind biogenic amines and the 
opioid and somatostatin peptide-binding receptors. A second aspartate at the extracellular 
end of helix 3 (D97 in m2 muscarinic receptor) is conserved less strictly among 
receptors that bind biogenic amines. It is conserved among the muscarinic receptors, 
most dopamine, and some 5-hydroxytrypamine and a-adrenergic receptors; glutamate is 
conserved at this homologous site in the 0-adrenergic and some a-adrenergic receptors 12 
Figure 1.4 Transmembrane helical structure of m2 muscarinic receptor. Consensus 
N-glycosylation sites (residues 2, 3, and 6) are indicated with small branched structures 
and the palmitoylation site (residue 457) is indicated with a zig-zagged line. The circled 
residues are positions that are highly conserved or have restricted variability in or near 
the transmembrane helices in the rhodopsin-like family of G protein-coupled receptors 
(68). KT N N N N M P G S E D  E  S K Q T C I  K I  V  T 
AD R P A KG NOIKNH 
NKED K S HG LSTSVT NEDOTI E D DR 
K  A P R D A V T E N CV Q G E E K E S S N D S T S V S  AV AS NM 14 
while acidic residues are missing in the histamine and octopamine receptors. There is a 
large concentration of aromatic residues in the extracellular ends of the transmembrane 
helices and the extracellular loops: W90, W148, F195, F396, Y403, and W400 are 
highly conserved in the rhodopsin-like G protein-coupled receptors, W99, Y196, Y430, 
and W427 among receptors that bind biogenic amines, and F75, Y80, Y83, W156, 
F162, W163, W165, F180, F188, F412, and Y426 among muscarinic receptors. 
Three consensus sequences for N-glycosylation appear in the extracellular amino 
terminus, but site-directed mutagenesis experiments on these sites in the m2 muscarinic 
receptor suggest that the glycosylation is not required for cell surface expression, ligand 
binding, or functional activity (72). Chemical modification and sequencing experiments 
(73) and site-directed mutagenesis studies (74) on the ml muscarinic receptor suggest 
that a disulfide bond exists between the extracellular end of helix 3 and second 
extracellular loops and that this bond is important for the formation of the ligand binding 
site. Serine and threonine phosphorylation sites occur in the third intracellular loop and 
the carboxyl-terminal tail of muscarinic receptors and are phosphorylated in both 
agonist-dependent and agonist-independent mechanisms (75-82). G protein-coupled 
receptors are typically palmitoylated post-translationally at one or two conserved cysteine 
residues in the carboxyl-terminal tail approximately 15 residues following the seventh 
transmembrane helix, and a single palmitoylation at residue 457 has been identified in 
the m2 muscarinic receptor (83) (Figure 1.4). 
G protein structure 
Agonist binding at G protein-coupled receptors results in the activation of one or 
more different types of G proteins that carry the extracellular signal to one or more 
intracellular effector sites. The most extensively studied system is the production of 
cAMP by adenylyl cyclase, which is stimulated by Gs and inhibited by Gi. Other G 
proteins activate phospholipase C, guanylyl cyclase, cGMP phosphodiesterase, calcium 15 
channels, and potassium channels. G proteins are membrane-associated heterotrimeric 
proteins consisting of an a subunit, which has the guanine nucleotide binding site and 
the GTPase activity, and the dimeric fily subunit. There are 23 distinct a subunits (the 
alternative splicing products of 17 genes), in four families (nf -5, -110, aq 1, and a12), 613 
subunits (84), and 12 y subunits (85). In the inactive form the a subunit is bound to 
GDP and is associated with the 137 subunit on the intracellular face of the plasma 
membrane or associated with receptor. The active receptor conformation, stabilized by 
receptor binding of ligand with a relatively high affinity, promotes the exchange of 
bound GDP for GTP on the a subunit and results in the dissociation of the a and the fry 
subunits. GTP hydrolysis results in subunit reassociation. G protein activation results in 
bifurcating signaling by both a and fily subunits (Figure 1.5). 
There are nine isoforms (types IIX) of membrane bound adenylyl cyclase (see 
Taussig and Gilman (86) and Houslay and Milligan (87) for reviews), and as stimulates 
all of them, ai inhibits types I, V, and VI (88, 89), 13y inhibits type I (90, 91) but 
stimulates types II (91) and type IV (92) synergistically with as. Phospholipase Cr3 
isozymes PLCI31, PLC[33, and PLC134 are stimulated by members of the actin family 
(93-97) and less so PLC 32. fay subunits stimulate PLCI32 and PLCI33 (98-102) and 
less so PLCf31, (see Exton (103, 104) for reviews). G protein-gated inwardly-rectifying 
potassium channels (GIRK1, 2, 3, 4)3 are activated by fry (105-109). The ail subunit, 
but not ai2 or 043, inhibits 13172-activated GIRK1 (110). Voltage-gated N-type calcium 
channels are inhibited by 13y (111-114). An additional role for the fry subunit is to 
promote homologous receptor desensitization by facilitating agonist-dependent receptor 
phosphorylation. Cytosolic G protein-coupled receptor kinases GRK2 and GRK3 are 
caused to associate near active receptors by binding to free membrane-associated fry 
3According to the standardized nomenclature also currently in use these are identifified as Kir3.1, 
3.2, 3.3, and 3.4; additionally, GIRK4 (Kir3.4) was previously identified as CIR and rcKATP. 16 
Figure 1.5 ReceptorG protein activation cycle. Inactive G proteins (G Gfly) freely 
GDP 
associate with either agonist-bound or unbound receptor (R). The receptor promotes the 
exchange of GTP for GDP by accelerating the dissociation rate of bound GDP. GTP-
bound heterotrimeric G protein dissociates into  Ga and Gsr subunits that activate 
effector systems. GTP hydrolysis on the  Ga  subunit increases the GaGsr affinity and 
the reassociated heterotrimeric G protein rejoins the pool of G proteins capable of 
associating with receptors. Receptors are thought to be in two states with respect to G 
proteins, inactive and active. In the active state the receptor is more effective in 
promoting guanine nucleotide exchange on the bound G protein and this active 
conformation has a higher affinity for agonists. In the presence of agonist the active 
conformation of the receptor is selectively bound, its concentration increases, and rate of 
GTP exchange through the cycle increases. This results in an increased steady-state 
concentration of active G protein subunits G and Gm,. 
GTP 17 
Figure 1.5 18 
subunits (115-117), (see Bohm et al. (118) for review). Perhaps as significant as the 
differences in specificity between a and 137 subunits are the differences in binding 
affinity of these subunits for their effectors. 13y subunits bind their effectors with 
approximately 100-fold lower affinity than a subunits and require higher concentrations 
to be effective. The Gi10 family are the most abundant G proteins, far exceeding the 
cellular concentration of other G protein families; in the brain Go is estimated to make up 
1-2% of membrane proteins (119). The combined effects of subunit effector affinities 
and relative G protein abundance effectively limit 07 effects to the Gvo family of G 
proteins, with some exceptions. 
Muscarinic receptor function 
Functionally the muscarinic receptor subtypes falls into two groups. The even 
numbered receptors (m2 and m4) inhibit adenylyl cyclase at low acetylcholine 
concentrations and at higher acetylcholine concentrations, modestly stimulate 
phospholipase C(3, activate inwardly-rectifying potassium currents, and inhibit voltage-
gated calcium channels. These effects are mediated by pertussis toxin-sensitive G 
proteins Gi and/or Go. The effects on adenylyl cyclase are via ai while the [37 subunits 
are responsible for the stimulation of phospholipase cp, stimulation of the inwardly-
rectifying potassium channels and the inhibition of voltage-gated calcium channels. The 
odd-numbered receptors (ml, m3, and m5) do not inhibit adenylyl cyclase but stimulate 
phospholipase C robustly via the pertussis and cholera toxin-insensitive aqi11 family. In 
addition to these primary effects there are numerous down-stream effects that result 
from muscarinic activation. The decreased cAMP concentration, mediated by m2 and 
m4 subtypes, has a negative effect on the cAMP-dependent protein kinase A. The 
increase in intracellular calcium concentration, the result of phospholipase Cf3 stimulation 
by m2 and m4 and especially ml, m3, and m5 subtypes, activates calmodulin while 19 
protein kinase C is synergistically activated by calcium and diacylglycerol, the second 
product of phospholipase CI3 stimulation. 
Receptor desensitization, which is the result of regulatory uncoupling of receptor 
from G protein and receptor endocytosis, is another down-stream effect of receptor 
activation and occurs via two pathways that result in receptor phosphorylation on serine 
and threonine residues. Homologous desensitization results from agonist-dependent 
phosphorylation on the same receptor and is mediated by G protein-coupled receptor 
kinases (GRKs). Heterologous desensitization is agonist-independent, the result of 
second-messenger-dependent protein kinase A and protein kinase C and can result from 
the activity of other receptors (see Bohm et al. (118) for review). GRKs include 
rhodopsin kinase (GRK1), 13-adrenergic receptor kinases 1 and 2 (GRK2 and GRK3), 
and GRK4, GRK5, and GRK6. GRK2 and GRK3 are activated by 13y subunits directly 
and unlike other 13y mediated effects can result from activity of low abundance G protein 
such as Gs irrespective of its typically high dissociation constant for fry subunits (120). 
The Py mediated activation occurs by promoting the membrane association of the 
enzyme from the cytosol. This can be achieved with low abundance G proteins because 
unlike phospholipase C13 and ion channel binding, which require the fly subunit to 
diffuse away from the receptor, a local high concentration of 13'y exists around the site of 
active receptor; it is the G protein receptor kinase that diffuses in the cytosol and is 
anchored to the membrane (117, 121). GRK2 and GRK3 are additionally inhibited by 
calcium-calmodulin (122, 123) and stimulated by protein kinase C phosphorylation 
(124). High specificity is usually achieved by high affinity in biological systems. The fry 
promoted translocation of GRK2 and GRK3 is one of the few examples of high 
specificity achieved in part because of the low affinity interaction of fry with these 
protein kinases. The high local concentration of 13y subunits occurs only near active 
receptors and quickly dissipates once the receptor becomes inactive. If the affinity of the 20 
protein kinases for fly was high then it would associate with receptors that were only 
occasionally active in addition to the highly active receptors, which are their appropriate 
site of action. 
The mechanism by which agonist binding on the cell surface is coupled to the 
activation of membrane associated G proteins was addressed by Rodbell (125) and De 
Lean et al. (126). Essentially the same idea that Rodbell called the disaggregation-
coupling model and De Lean et al. called the ternary complex model described a three 
component system made up of hormone, receptor, and G protein that are free to interact 
by mass-action to form a complex that activates effector systems. The model, now 
known only as the ternary complex model, is capable of explaining several observed 
aspects of hormone activation and inhibition of adenylyl cyclase including the 
dependence of hormone activation on the presence of GTP, the ability of sub-saturating 
concentrations of hormone to fully activate/inhibit the effector, and the heterotrophic 
binding of hormone/agonists to receptors and the effect of GTP on this binding. The 
application of this model to the explanation of muscarinic receptor stimulation of 
phosphatidylinositol and inhibition of adenylyl cyclase is the subject of Chapter 2. 
The best understood functional role of muscarinic receptors is in the heart, where 
the m2 subtype is expressed. Sympathetic and parasympathetic innervation of cardiac 
muscle and pacemaker cells of the sinoatrial node are responsible for the regulation of 
heart beat and force of contraction. Norepinephrine released from cardiac sympathetic 
neurons mediates the sympathetic response, increasing the rate and the force of 
contraction, while acetylcholine released from the vagus nerve mediates the 
parasympathetic response decreasing the rate and the force of contraction. 01-Adrenergic 
receptors in these cells respond to the increased extracellular concentration of 
norepinephrine by stimulating the production of cAMP. In turn, cAMP-dependent 
phosphorylation of L-type calcium channels causes the calcium current to increase. 21 
m2 Muscarinic receptors respond to low concentrations of acetylcholine by inhibiting the 
production of cAMP and to relatively high concentrations by stimulating inwardly-
rectifying potassium channels via direct binding of the fry subunit of Gi. It is thought 
that activation of this potassium channel is responsible for the decreased heart rate that 
Loewi first described in 1921, the result of stimulating the vagus nerve of isolated frog 
hearts. 
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Chapter 21 
Porcine m2 Muscarinic Acetylcholine Receptor-Effector
 
Coupling in Chinese Hamster Ovary Cells2
 
Abstract 
The relationship between porcine m2 muscarinic receptor coupling to inhibition 
of cAMP formation and stimulation of phosphatidylinositol metabolism in Chinese 
hamster ovary cells was examined. Reduction of the number of receptors per cell with 
the slowly dissociating antagonist ()-quinuclidinyl benzilate caused a decrease in 
maximal response with no effect on EC50 for coupling to phosphatidylinositol 
metabolism. Inhibition of cAMP formation showed the opposite dependence with no 
effect on maximal response but an increase in EC50 value as receptor density decreased. 
Pilocarpine appeared to be a partial agonist at low cell receptor density but displayed full 
agonism at higher receptor density. These results are compatible with a two-state model 
describing m2 muscarinic receptor acting via two different G proteins. This model is 
compatible with observations of negative antagonism where antagonists stimulated 
cAMP formation in adenylyl cyclase inhibition assays, and can also be used to estimate 
receptor affinities for G proteins in systems which display negative antagonism. 
1This chapter was originally published in the Journal of Biological Chemistry 270, 15485-15493, © 
1995 by The American Society for Biochemistry and Molecular Biology, Inc., and is reprinted with 
permission. 
2This work was supported by the National Institutes of Health Grants HL23632 and ES00210. 33 
Introduction 
mAcChRs3 belong to the family of G protein-coupled hormone receptors. The 
genes coding for five different mAcChR subtypes (ml to m5) have been cloned and 
expressed (1-3). The even-numbered subtypes couple preferentially to inhibition of 
cAMP formation and the odd-numbered subtypes to stimulation of phospholipid 
metabolism (4). The m2 subtype also couples to activation of inwardly-rectifying potas­
sium channels in the heart (4). When cloned genes for mAcChR subtypes are expressed 
in cell lines not normally containing mAcChRs the nature of receptor-effector coupling 
becomes unclear, presumably depending on the complement of G proteins and effector 
systems in the cell line and the level of expression of the exogenous receptor (5-8). 
The interpretation of the agonist binding properties of mAcChRs has been 
challenging because data often did not conform to accepted models. Muscarinic agonists 
appear to displace radiolabeled antagonists over 5-8 orders of magnitude in 
concentration and a careful analysis of the ligand binding properties of m2 receptors in 
hamster heart homogenates suggested that the ternary complex model was not 
compatible with experimental observations (9). 
13-adrenergic receptor coupling to Gs has been analyzed using the ternary 
complex model (10) initially proposed by Rodbell (11) and a mobile receptor model 
proposed by Whaley et al. (12). The ternary complex model was extended to describe 
negative antagonism (13), inverse agonist activity (14), and a constitutively active 13­
adrenergic receptor mutant (15). It was also used to explain coupling of m2 mAcChR to 
inhibition of cAMP formation in rabbit myocardium (16). 
3The abbreviations used are: mAcChR, muscarinic acetylcholine receptor; CHO, Chinese hamster 
ovary; G protein, guanine nucleotide-binding protein; NMS, S- ( )- N- methylscopolamine; PI, 
phosphatidylinositol; PTX, pertussis toxin; QNB,  benzilate; Gpp(NH)p, guanyl­
imidodiphosphate; GDP13S, Guanosine-5'-0-(2-thiodiphosphate); KL, KM, and KH, the low, medium, 
and high affinity dissociation constants, respectively. 34 
Because the pm2 mAcChR subtype expressed in CHO cells couples to inhibition 
of cAMP formation and stimulation of hormone-sensitive phospholipase C, it provided 
an attractive system to study the relationship between receptor-effector coupling and 
agonist binding properties. The results of this study suggest that although the manner in 
which the EC50 and maximum response for the two effector systems depends on 
receptor density is different, both results are compatible with a two-state model that 
allows for a stronger affinity of the receptor-agonist complex for the G protein that 
mediates cAMP inhibition than the G protein that couples to PI stimulation. The model 
also accounts for partial agonism and negative antagonism. Allowing for a receptor state 
that is not physiologically competent gave agreement between ligand binding results and 
physiological assays. 
For more than 30 years similar results were explained in terms of spare receptors 
or receptor reserves and spare mediators or G protein reserves (17-19). These 
explanations were useful in rationalizing the link between receptor occupancy and 
physiological response but lacked a clearly defined mechanistic interpretation. The model 
presented here expands spare receptor theory to quantitatively account for the role of G 
protein mediators in receptoreffector coupling. 
Experimental Procedures 
Stably transfected CHO cells overexpressing pm2 mAcChR (2), mAcChR­
enriched membrane preparations (20)4, and ligand binding procedures (21) were 
previously described. 
4G. L. Peterson, A. Toumadje, W. C. Johnson, Jr., and M. I. Schimerlik, submitted for publication. 35 
Materials 
Radioisotopes were purchased from DuPont-NEN, pertussis toxin and cholera 
toxin from List Biological Laboratories, G protein antagonist-2 (Lot P1746) and Ro 20­
1724 from Biomol Research Labs, and EGTA-AM from Molecular Probes. Polyclonal 
antibody against Gai1 /i2 and the calcium ionophore A23187 were obtained from 
Calbiochem. Polyclonal antibodies to the G protein a subunits of Gol (Z811), G13 
(B860), Gz (X264), and GOB (B597) were the kind gift of Paul Sternweis. 
Effector Coupling 
PI stimulation was determined in CHO cells expressing pm2 mAcChR plated at 
2 x 105 per 35-mm plate and incubated in 1 tCi/ml [3H]myo-inositol at 37 °C for 48 h. 
Ligands were added and inositol 1-phosphate accumulation was measured after 30 min 
at 37 °C as described by Lee et al. (22). cAMP production in fresh membrane 
preparations was determined by monitoring the conversion of [32P]ATP to [32P]cAMP 
at 30 °C for 15 min following the addition of 10 tM forskolin according to the method 
of Johnson and Salomon (23). Adenylyl cyclase activity was determined in attached cells 
in the presence of 10011M isobutylmethylxanthine and 50 p,M Ro 20-1724 after 
exposing the cells to 8 liCihnl [3H]adenine for 2-3 h. The 20 min assay at 37 °C was 
started by the addition of 40 p.M forskolin. Some assays used cholera toxin (500 ng/ml 
for 2 h) in place of forskolin; these resulted in identical EC50 values but the maximal 
response was less. [3H]cAMP was determined according to the method of Salomon 
(24). 
To examine receptoreffector coupling as a function of receptor number, 
attempts were made to isolate cell lines stably expressing pm2 mAcChRs at varying 
levels. These were unsuccessful, as were attempts to reduce receptor number with the 
alkylating agent benzilylcholine mustard, which removed only 80-90% of the total 
[3H]NMS binding sites from cell lines containing 1-2 x 106 receptors/cell. An alternative 36 
approach using the slowly dissociating antagonist QNB was adopted. Varying amounts 
of QNB were added and after 1 h at 37 °C the plates were rinsed twice with media to 
remove free QNB. Functional assays were then initiated and [3H]NMS binding sites 
determined in a parallel experiment. Receptors and G proteins exist in a two-dimensional 
environment while ligands are in three-dimensional solution. In order to assess the data 
in the proper dimensional context, receptor and G protein concentrations and receptorG 
protein dissociation constants are given as two-dimensional parameters. The two-
dimensional receptor concentration was calculated by dividing the receptors expressed on 
the cell surface by the estimated cell surface area (10-7 dm2). 
Data Analysis 
Functional assays were fit to Equation 1, where [x] is the agonist concentration, 
maxi,2 are the maxima of the inhibitory and stimulatory portions of the curve, min is the 
minimum of the curve, and p1,2 are the respective slope factors. For adenylyl cyclase 
assays that showed only an inhibitory phase the first two terms were used and for assays 
of PI stimulation the first and last terms were used. 
max  min  max2  min
CPM = min + 
[x] 
131 
1±((EC50s)  P2 
(EC50i)  [x]  (Eq. 2.1) 
Ligand binding data were analyzed by nonlinear regression to a hyperbolic binding 
equation for [3H]NMS and [3H]QNB or by competition with either radiolabeled 
antagonist. Agonist binding data were fit assuming three noninteracting classes of 
agonist sites that bound antagonist with the same dissociation constant. Under these 
assumptions the total labeled antagonist specifically bound, [RI,], is the sum of that 
bound at each subclass of agonist binding sites: 37 
[RoiX[L,0] [NM
[Ril = L 
i=1 K +  [A]+[L01[RL] 
(Eq. 2.2) 
[Roi] equals the total concentration of receptor site i; [L0], the total labeled antagonist 
concentration; [A], the total agonist concentration (equal to the free concentration since no 
displacement occurs until [A] > X[Roi] ); K, the dissociation constant for radiolabeled 
antagonist and Ki the dissociation constant for the agonist at site i (referred to as Kw KM, 
and KL, the high, medium, and low affinity constants)5. 
A simpler model of two noninteracting classes of sites gave inadequate fits to 
most of our agonist binding data. In our analysis K and [Lo] are supplied from 
independent determinations and held constant. Values for F,, the fraction of each class of 
site, were calculated from the fitted parameters R0  .  Some agonist binding data were fit 
to a two-state model (11), often referred to as the ternary complex model, that was 
expanded to account for a class of receptors that are incapable of interacting with G 
proteins. This model is presented in Scheme 2.1, where R is the receptor state capable of 
associating with G protein and R' is not. M is the dissociation constant of the RG 
complex (equal to K1 in the Appendix to this Chapter), KM and KL have the same 
meaning as above, and a is a dimensionless parameter relating M and KM to the other 
two binding constants in this closed thermodynamic cycle. Data fitting to this model 
required an iterative numerical method to calculate the bound labeled antagonist (LR + 
LRG + LR'). The parameters in Equations 2.1 and 2.2 and the model in Scheme 2.1 
were estimated by nonlinear least-squares procedures using Marquardt's algorithm (25) 
and are reported as the mean and standard deviation of several determinations. 
5Expanded solutions of these equations appear in the Appendix to this dissertation. 38 
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Results 
Muscarinic agonists decreased cAMP levels at low agonist concentrations. A 
stimulatory phase at high agonist concentrations was observed in cells overexpressing 
receptor (Figure 2.1A) and in membrane preparations from those cells (Figure 2.1C). 
The agonist-induced stimulation of cAMP production was prevented by the addition of 
10 I_tM ()-hyoscyamine, a muscarinic antagonist. The effect was not seen in cells 
expressing less than 1 x 105 sites/cell or in membrane preparations with less than 10 
pmol [3H]NMS sites/mg protein. Unlike the inhibitory phase, the magnitude of the 
stimulatory phase was strongly dependent on pm2 mAcChR expression levels. Similar 
to the effect of receptor number on the EC50 for the inhibitory phase, decreasing receptor 
site density increased the EC50for stimulation. The stimulation of cAMP formation was 
mediated by G proteins since it was eliminated in membrane preparations in the presence 
of GDPOS (Figure 2.1C). 39 
Figure 2.1. Coupling of the pm2 mAcChR to effectors in CHO cells and 
membranes. The cells were expressing mAcChR at levels approximately 10-fold 
greater than porcine atrial tissue (20), while the enriched membranes were approximately 
60-fold greater. The data were analyzed according to Equation 2.1 and parameter values 
for the fitted lines are shown ± asymptotic standard errors. The values in parentheses are 
the % inhibition = 100 x (1  min/maxi) when following the EC50i value, the % 
stimulation = 100 x ( (max2  min)I(maxi  min)) when following the EC50s. value, or 
fold stimulation when following the EC50 for PI stimulation. 
A, Inhibition and stimulation of cAMP accumulation in CHO cells at different receptor 
site densities:  ,  1.8 x 106 [3H]NMS sites/cell (3.9 x 10-11 moldm-2), EC50i = 26.3 
± 3.0 nM (65.8 ± 1.6%), EC50s = 6.96 ± 0.62 .1.M (234 ± 12%); 0 ,  9.4 x105 sites/cell 
(2 x 10-11 moldm-2), EC50i = 69.3 ± 5.5 nM (71.4 ± 1.3%), EC50,s. = 18.1 ± 1.9 1.IM 
(118 ± 4%); (X) 3.6 x 105 sites/cell (7.7 x 10-12 moldm-2), EC50i = 225 ± 18 nM 
(66.3 ± 1.2%), EC50s = 117 ± 33 tM (37.3 ± 2.0%);  ,  1.3 x 105 sites/cell (5.5 x 10­
12 mdm-2), EC50i = 753 ± 53 nM (65.7 ± 0.6%). Data were fit with slope factors pl 
and p2 = 1. 
B, Stimulation of PI metabolism in CHO cells at different receptor site densities:  , 
1.8 x 106 sites/cell (3.6 x 10-11 moldm-2), ECK). 0.61 ± 0.31 µM (2.22-fold); 0, 1.6 
x 106 sites/cell (3.2 x 10-11 moldm-2), EC50= 0.90 ± 0.31 plvl (2.26-fold); X, 7.6 x 
105 sites/cell (1.5 x 10-11 moldm-2), ECK, = 1.2 ± 0.7 tM (1.82-fold); , 1.9 x 105 
sites/cell (3.8 x 10-12 moldm-2), EC50= 1.2 ± 0.8 i_tM (1.82-fold); IN, 1.0 x 105 
sites/cell (2 x 10-12 moldm-2), EC50= 0.91 ± 0.27 tM (1.58-fold). Data were fit with 
slope factor p2 = 0.6. 
C, Inhibition and stimulation of cAMP accumulation in membranes prepared from 
CHO cells. In membranes expressing 257 pmol sites/mg protein the fitted parameter 
were: EC50i = 0.138 ± 0.07311M (50.8 ± 6.0%), pl = 0.5 (fixed), EC50s = 52.9 ± 7.0 
tiM (194 ± 14%), p2 = 0.864 ± 0.009 with 10 !_tM GTP in the assay, and EC50i = 1.79 ± 
0.18 µM (60.9 ± 0.6%), pl = 0.675 ± 0.038 with 50 i_tM GDP13S. 
D, The effect of antagonist on cAMP accumulation measured in whole cells. The 
parameters were: QNB, EC50i = 3.5 ± 0.7 nM, p2 = 1.5 (fixed); NMS, EC50i = 5.2 ± 
0.9 nM, p2 = 1.6 ± 0.3; and hyoscyamine, EC50i = 7.8 ± 1.2 nM, p2 = 1.3 ± 0.2. The 
receptor site density was 1.4 x 106 sites/cells (4.7 x 10-11 moldm-2). 40 
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The inhibition and stimulation of adenylyl cyclase in CHO cells were most easily 
seen when the cyclase was stimulated with forskolin or cholera toxin. In the absence of 
these exogenous stimulators inhibition and stimulation were evident but near the limit of 
sensitivity of our assay (data not shown). If the stimulatory phase was the direct result of 
strong Gs activation then a large increase in cAMP in the absence of forskolin or cholera 
toxin should have been observed similar to the effect seen in CHO cells expressing the 
P-adrenergic receptor (26). Treating the CHO cells with 100 ng/ml pertussis toxin, 
which ADP-ribosylates and inactivates Gi and Go, for 12 h prior to assay eliminated the 
Gi-mediated inhibition while not affecting the stimulatory phase. 
Antibody preparations were unable to block the stimulatory phase: anti-ai raised 
to the common carboxyl-terminal decapeptide of Giat and Gica (27); anti-ococ, raised 
to the common carboxyl-terminal 12 amino acid peptide of aq and an; anti-az, -a13, 
and -a0B , raised to carboxyl-terminal 17, 16, and 15 amino acid peptides, respectively, 
of their corresponding a subunits (28). G protein antagonist-2 (29), a peptide capable of 
competing with receptors for Gi, Go, and Gs was also unable to affect the stimulation of 
adenylyl cyclase at concentrations up to 10011M. 
Since intracellular Ca2+ released due to pm2 mAcChR-mediated activation of PI 
turnover stimulates Type I and III adenylyl cyclases, the effect of the Ca2+ ionophore 
A23187 (30) and the Ca2+ chelator EGTA-AM (31) on pm2 mAcChR-mediated cAMP 
accumulation was examined. The cAMP level was elevated less than 15% in the 
presence of 10 µM A23187 and extracellular [Call equal to 300 µM, conditions that 
produced the maximum effect. Extracellular [Ca24-] in excess of 1 mM reduced cAMP 
accumulation. EGTA-AM at 90 [IM had no effect on cAMP levels in the presence of the 
phosphodiesterase inhibitor isobutylmethylxanthine (100 liM). 
The stimulatory effect seen in CHO cells expressing the pm2 mAcChR was also 
seen in CHO cells expressing the hml mAcChR subtype and in membrane preparations 43 
from those cells. Pertussis toxin did not affect cAMP stimulation in hm 1 expressing 
CHO cells and the EC50 for stimulation with carbachol (4.6 ± 1.4 jiM, 1 x 106 
[3H]NMS sites/cell) occurred at similar EC50 for PI stimulation in those cells (3.3 ± 1.8 
[tM). Our results are similar to those reported by Peralta et al. (32) for human ml 
mAcChR expressed in a cloned human kidney cell line. Additional evidence that the 
stimulatory effect did not involve a G protein primarily coupled to PI turnover came 
from experiments on a site directed mutant (D69N) which coupled to the inhibition of 
cAMP accumulation when oxotremorine M was the agonist and to stimulation of cAMP 
accumulation when acetylcholine was the agonist while not coupling to PI turnover at 
al1.6 The stimulation was not a result of an agonist-dependent inhibition of a cAMP­
specific phosphodiesterase. Control experiments in membranes conducted in the 
presence of [3H]cAMP showed no change in [311]cAMP while [32P]cAMP production 
first decreased and then increased with increasing carbachol. 
The relationship between receptor site density and coupling to physiological 
effectors is presented in Figures 2.1A and 2.1B. Figures 2.2-2.5 show the relationship 
between EC50, maximal effect, and receptor density. Over the receptor levels examined, 
the maximal percent inhibition of cAMP formation (Figures 2.1A and 2.2) was 
unaffected by receptor density for the full agonists acetylcholine, oxotremorine M, and 
carbachol. The partial agonist pilocarpine gave the same maximal inhibitory cAMP 
response at receptor densities greater than 2 x 10-11 moldm-2 and a significantly lower 
response at receptor densities less than 5 x 10-12 moldm-2. The EC50i values for the 
four agonists were dependent on the receptor density, decreasing as receptor density 
increased. Data were analyzed as plots of EC50i versus 1/[R0] (Figure 2.3) according to 
the model in Scheme 2.2. Initial slopes were taken to equal Equation 2.A13. Antagonists 
6W. K. Vogel and M. I. Schimerlik, unpublished observation. 44 
Figure 2.2. The effect of pm2 mAcChR on the maximal inhibition of forskolin­
stimulated cAMP formation in whole cells. Data are from Figure 2.1A and other 
experiments. Average values (line plotted over the range averaged) were 80.0 ± 3.6%, 
65.4 ± 5.1%, 76.2 ± 2.5%, and 62 ± 11% for acetylcholine (AcCh), carbachol (Garb), 
oxotremorine M (Oxo M), and pilocarpine (Pilo), respectively. 
Figure 2.3. The effect of pm2 mAcChR on the EC50 for cAMP inhibition in whole 
cells. Data are from Figure 2.1A and other experiments. The data near the origin were fit 
to a linear function resulting in slope values of 2.3 ± 0.3 x 10-19 mo12dm-5, 5.4 ± 2.5 x 
10-19 mo12dm-5, 4 ± 6 x 10-20 mo12dm-5, and 7.6 ± 0.7 x 10-17 mo12dm-5, and 
intercept values of 8 ± 16 x 10-10 M, 2 + 1 x 10-8 M, 7 ± 3 x 10-9 M, and 5 ± 97 x 
10-8 M for acetylcholine (AcCh), carbachol (Garb), oxotremorine M (Oxo M), and 
pilocarpine (Pilo), respectively. 
Figure 2.4. The effect of pm2 mAcChR on fold maximal response for PI 
stimulation in whole cells. Data are from Figure 2.1B and other experiments. The lines 
in the plot are to show the trend in the data and were not interpreted mechanistically. 
AcCh, acetylcholine; Garb, carbachol; Oxo M, oxotremorine M; Pilo, pilocarpine. 
Figure 2.5. The effect of pm2 mAcChR on the EC50 for PI stimulation in whole 
cells assays. Data are from Figure 2.1B and other experiments. Average values were 0.4 
± 0.2 [tM, 1.2 ± 0.51.tM, 1.0± 0.5 µM, and 10 ± 41.IM for acetylcholine (AcCh), 
carbachol (Garb), oxotremorine M (Oxo M), and pilocarpine (Pilo), respectively. 45 
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stimulated cAMP accumulation above basal level with EC50 values that were greater 
than their dissociation constants. The dissociation constants determined in cells were 
13.7 ± 2.4 pM (n = 4) for QNB and 239 ± 37 pM (n = 11) for NMS (hyoscyamine was 
not determined). The effect of antagonists on basal PI turnover could not be reliably 
assessed because of base line variability. 
Coupling of pm2 mAcChRs to PI stimulation in CHO cells behaved in a 
different manner than coupling to inhibition of cAMP formation. Fold maximum 
stimulation appeared to increase with increasing receptor density (Figure 2.4). The EC50 
values did not depend on receptor concentration for PI stimulation for all four agonists 
(Figure 2.5). 
Ligand binding data for agonists were also analyzed for isolated cell lines 
expressing pm2 mAcChRs at three different levels; results are shown for carbachol 
(Figure 2.6), where data were analyzed according to Equation 2.2 in the presence or 
absence of Gpp(NH)p. The values of the dissociation constants for the three classes of 
sites were relatively constant for all expression levels; however the value of F1, the 
fraction of high affinity sites, decreased from 56% at the lowest specific activity to 9% at 
the highest level of expression. The class of sites having intermediate affinity for 
carbachol, F2, increased from 24 to 68% as expression levels increased, while the lowest 
affinity site, F3, remained constant at about 20% of the total [311]NMS sites. Addition of 
Gpp(NH)p resulted in a loss of the high affinity sites and an equivalent increase in the 
sites having intermediate affinity for carbachol. Oxotremorine M and acetylcholine also 
appeared to interact with three classes of sites while data for pilocarpine were best fit 
assuming only two classes of binding sites. The dissociation constants for agonists are 
summarized in Table 2.1. 50 
Figure 2.6. [3H]NMS displacement by carbachol in CHO cell membranes 
expressing high, intermediate, and low levels of pm2 mAcChR. The top pair: 150 
pmol/mg pm2 mAcChR ± 50 pM Gpp(NH)p, FH = 9 ± 1%, FM = 68 ± 1%, FL = 23 ± 
1%, in the absence of Gpp(NH)p, FH = 0, FM = 77 ± 1%, FL = 23 ± 1% in the presence 
of Gpp(NH)p; KH = 1.6 ± 1.2 nM, KM = 1.99 ± 0.10 p.M, KL = 27 ± 14M. The center 
pair: 38 pmol/mg pm2 mAcChR ± 50 pM Gpp(NH)p, FH = 27 ± 1%, FM = 52 ± 1%, 
FL = 21 ± 1%, in the absence of Gpp(NH)p, FH = 0, FM = 82 ± 1%, FL = 18 ± 1% in 
the presence of Gpp(NH)p; KH = 1.9 ± 0.5 nM, KM = 1.34 ± 0.08 gM, KL = 19.5 ± 0.9 
The bottom pair: 5 pmol/mg pm2 mAcChR ± 100 pM Gpp(NH)p, Fri = 56 ± 2%, 
FM = 24 ± 2%, FL = 20 ± 3%, in the absence of Gpp(NH)p, FH = 0, FM = 81 ± 2%, FL 
= 19 ± 2% in the presence of Gpp(NH)p; KH = 17 ± 3 nM, KM = 1.0 ± 0.1 pM, KL = 31 
± 1 ILIM. In the presence of Gpp(NH)p no significant FH fraction was found and the data 
were fit to two independent classes of sites. The parameter values for the fitted lines are 
shown ± asymptotic standard errors. 51 
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Table 2.1. Agonist binding data for pm2 mAcChR expressed in CHO cell 
membranes 
Agonist  Kg (nM)  n  KM (1.1,M)a  it  KL (.tM)  n 
6 acetylcholine  1.18 ± 0.34  4  0.30 ± 0.15  7  7.4 ± 5.4 
oxotremorine M  1.6 ± 1.6  5  0.32 ± 0.23  7  9.9 ± 5.1  5 
carbachol  3.3 ± 2.8  9  1.05 ± 0.37  19  20.2 ± 8.5  19 
pilocarpine  252 ± 87  4  18.6 ± 8.7  4  _b 
aKM values determined in cells at 37 °C in culture media, while not strictly at equilibrium, are 
comparable: 0.26 ± 0.06 (n = 4), 0.51 ± 0.33 (n = 5), 2.5 ± 1.3 (n = 5), and 17.4 ± 9.0 pM (ft = 3) 
for acetylcholine, oxotremorine M, carbachol, and pilocarpine respectively. bThe partial agonist 
pilocarpine fits to two rather than three independent sites; of these two only the lower affinity KM is 
seen in the presence of Gpp(NH)p. Binding constants are reported as the mean and standard 
deviation of several determinations (n)  . 
Discussion 
The coupling of mAcChRs to both stimulation of PI metabolism and inhibition 
of cAMP formation in CHO cells was examined during a previous study (5); however, 
the results presented here differ from the earlier results. The previous study found that 
the EC50 and the maximum percent inhibition for cAMP formation both appeared 
constant, while for the stimulation of PI metabolism the EC50 decreased and the 
maximal response increased with increasing receptor concentration. The reason for the 
differing results is not certain; however, the two studies used different approaches. In the 
previous study, responses were measured for an average number of receptors/cell during 
continuous amplification of pm2 mAcChR expression, while in this study clonal cell 
lines were used and receptor concentration reduced with antagonist. An alternative 
explanation is that the two CHO cell lines used simply had different properties. The 
previous results do not show a stimulatory phase in cAMP formation assays; a robust 
stimulatory phase is reported here under similar conditions. The possibility of 
differences in CHO cell lines is also supported by the observation that the CHO cell line 53 
used for these studies contained Gaz 7 not found by Dell'Acqua et al. (33) in their CHO 
cell line. 
Data suggest that the stimulation of cAMP formation seen at high agonist and 
receptor concentrations was mediated by the pm2 mAcChR and an unidentified G 
protein. The high agonist and receptor concentration requirement further suggests that the 
interaction is weak. Dittman et al. (34) examined mAcChR stimulation of cAMP 
formation in a well-defined system in which HEK 293 cells were transfected with the 
chick m4 mAcChR and calmodulin-sensitive type I and type III adenylyl cyclases. Their 
observations were similar to those reported here and because the adenylyl cyclase 
isoforms used were not stimulated by G protein fry subunits, they were able to attribute 
the stimulatory phase to direct receptor interactions with Gs. Since the adenylyl cyclase 
isoforms present in CHO cells are not yet known, it is not possible to resolve the 
question for this system. A direct stimulation via Gs, however, is not consistent with the 
model presented in the Appendix to this Chapter, which predicts EC50s values less than 
or equal to the highest agonist dissociation constant observed. A possible explanation for 
the stimulatory phase seen in CHO cells is that this stimulation was the result of a G 
protein fry subunit. The model in the Appendix to this Chapter must be extended to 
account for the stimulatory phase we observe in adenylyl cyclase assays. 
A major goal of this research was to try to find a common general mechanism 
that could explain the differing dependence of PI stimulation and inhibition of cAMP 
formation on pm2 mAcChR density and to relate these results to agonist binding data 
from CHO cell membranes. Agonist binding data over all levels of receptor expression 
were not compatible with a simple two-state mechanism as shown previously by Wong 
et al. (9). Data could however be fit assuming either three noninteracting classes of sites 
7J. Robishaw, unpublished results. 54 
or an extended ternary complex model. In the three-site model the highest agonist 
affinity state is attributable to receptors complexed with G proteins and the intermediate 
affinity to free receptors. This assignment is based on the ability of Gpp(NH)p to 
quantitatively convert F1 to F2 in the agonist competition curves. The lowest affmity state 
is undefined molecularly but is not capable of interacting with G proteins. Possible 
explanations for this are differences in compartmentalization, posttranslational 
modification, or state of aggregation. Using the three-site model simplified data analysis 
since fitting routines converged satisfactorily, however, it lacked an underlying 
mechanistic basis. Therefore, fitting agonist binding data to an extended ternary complex 
model was explored. There were two disadvantages to this approach. First, the value for 
[G0], the total amount of accessible G protein, was solved as a fitting parameter and 
could not be determined experimentally. Second, data fitting to the model often resulted 
in local minima, gave poorly determined values, or failed to converge. Comparison of 
the two approaches indicates that the fitted values for KL = [R] [A] l[AR1 and KM = 
[R][A]l[AR] apply for both analyses. In the three-site model, KH = [RG][A]l[ARG] which 
equals KM /a in the extended ternary complex model. Thus the value for a from the 
extended ternary complex model equals Km/KH from the three-site fits. The ternary 
complex model fit also provides a value for M, the binding constant of G to R; however, 
this parameter is ambiguous since the local concentrations of R and G are unknown and 
exist in a two-dimensional, rather than three-dimensional system. Since there were few 
practical advantages of fitting to the ternary complex model binding data were routinely 
analyzed assuming three classes of noninteracting sites. 
The model presented in Scheme 2.2 describes pm2 mAcChRG protein 
interactions in terms of two states assuming that the lowest affinity receptor state is not 
physiologically competent. The assumptions of the derivation are that binding steps 
equilibrate rapidly and that the activated G protein (G) is in a steady state. Since the time 55 
Scheme 2.2 
courses of cAMP and inositol 1-phosphate formation are linear over the assay time 
periods, these assumptions would appear to be reasonable. Model simulations at two 
different receptor-G protein affinities are presented in Figure 2.7. The shape of the 
function depends on the G protein concentration relative to its affinity for the receptor, 
and the affinity of the G protein for the receptor relative to the affinity of the agonist for 
the receptor. Figure 2.7A illustrates conditions where the receptor affmity for G is 105 
greater than receptor affinity for agonists while in Figure 2.7B the affinity is 10-fold 
greater. If experimental conditions allowed the determination of EC50, [G 'J., and 
[G 1  over a 10-fold range of [Ro], then the model predicts that a G protein-coupled 
receptor eliciting multiple responses via different G proteins can exhibit different types of 
behavior depending on the affinity of receptor for G proteins. Coupling to a relatively 
high affinity G protein would result in an EC50 that decreases with increasing receptor 
concentration while the [G'ss]max remains unchanged. Coupling to a low affinity G 
protein would result in both the EC50 decreasing and the [G J. increasing with 56 
increasing receptor concentration. Coupling to a lower affinity G protein would result in 
a constant EC50 while [Gcs]. increases with increasing receptor concentration. 
Decreasing the G protein concentration has an effect similar to decreased receptor affinity 
for G. The inhibitory cyclase response can be explained by coupling via a relatively high 
affinity G protein, while the stimulation of PI metabolism can be explained by coupling 
via a different, lower affinity G protein. 
Partial agonists are ligands that result in less than the maximal physiological 
response seen with another ligand termed a full agonist. A ligand that appears to be a 
partial agonist in one system can appear elsewhere to be a full agonist (35-37). At high 
receptor concentrations pilocarpine appeared to be a full agonist, having about the same 
maximal cyclase inhibition as acetylcholine, oxotremorine M, and carbachol. At lower 
receptor concentrations pilocarpine, unlike the full agonists, resulted in decreasing 
maximal cyclase inhibition with decreasing receptor concentration (Figure 2.2). The 
model in the Appendix to this Chapter explains both of these observations. The maximal 
response, [G cs,ffm., reaches a maximum that is independent of agonist as receptor 1
concentration approaches infinity (Equation 2.A15). Provided that the receptor affinity 
for G is much greater than receptor affinity for A, K3<< K2, the maximal response is 
independent of agonist at finite but relatively high receptor concentrations. Maximal 
response is dependent on agonist at lower receptor concentrations; and the placement and 
sharpness of the transition from agonist-independent to agonist-dependent maximal 
response is also dependent on the ratio of K3 to K2 (Figure 2.7A). The full agonists were 
found to have KH = K2  2 nM while the value for pilocarpine was 125-fold greater 
(Table 2.1). A limited range of receptor concentrations was examined and since the 
maximal inhibition of cyclase was constant for the three full agonists, our experiments 
were conducted in the agonist-independent range of receptor concentrations for this ratio 
of K3 to K2. For pilocarpine, the 125-fold difference in the ratio of K3 to K2 resulted in a 57 
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Figure 2.7. Theoretical relationship for the EC50, [G-ss]min, and [G'sj. vs 1/[Rol for 
the model. The model was calculated with the following parameter values: K2 = 2 nM, 
K4 = 1 1-049 [GO] = 1 x 10-11 MOIM-2, k5= 0.8 s-1, k, = 1 s-1, k9 = 0.2 s-1, K1= 1 x 
10-11 moldm-2 (A) and 1 x 10--7 moldm-2 (B), K3 = 2 x 10-14 moldm-2 (A) and 1 x 
10-10 moldm-2 (B). 58 
transition from agonist-independent to agonist-dependent maximal response that was 
broader and shifted to higher receptor concentrations than for the three higher affinity 
agonists. Thus pilocarpine requires a greater receptor concentration to reach the same 
limit of maximal inhibition than the higher affinity agonists. 
The model predicts that k5, a composite rate constant for G protein activation via 
the ARG complex, is agonist independent. Since k7, the rate of inactivation of G', and K1, 
the dissociation constant of the RG complex, are ligand independent, the initial 
asymptotic slope of an EC50 vs 14Ro] plot is proportional to K2 (Equation 2.A13). The 
ratio of the slopes in Figure 2.3 to the KH = K2 values in Table 2.1 are: 2.0 ± 0.6 x 10-10 
moldm-2, 1.6 ± 1.6 x 10-10 moldm-2, 2.5 ± 5.0 x 10-10 moldm-2, 3.0 ± 1.1 x 10-10 
moldm-2, for acetylcholine, carbachol, oxotremorine M, and pilocarpine, respectively, 
values that are equal within experimental error. The system did not allow effector 
coupling to be assessed over a sufficiently large receptor concentration range to estimate 
the model parameters independently, but was sufficient to confirm previous studies in a 
reconstituted system (38) which indicated that the difference between the full agonist 
carbachol and the partial agonist pilocarpine was the affinity of the receptor-agonist 
complex for G,, not the rate constant for G protein activation. In that study it was also 
found that the receptor-carbachol complex had a 4-fold higher affinity for G, than the 
receptor-pilocarpine complex (i.e. (K3)pilocaipine/(Klarbachoi= 3.73  1.35). While this ratio 
cannot be obtained from the model in the Appendix to this Chapter, it is possible to 
obtain it from ligand binding data. Substituting the values from Table 2.1, the ratio 
equals 4.3 ± 4.7. Although poorly determined, it agrees well with the value obtained 
from the reconstituted system. 
The model accounts for the negative antagonism observed in cyclase inhibition 
assays (Figure 2.1D). According to Scheme 2.2 the RG complex is the only route to G' 
in the absence of agonist. In the presence of agonist the more productive route (provided 59 
k5 > k9) via ARG contributes to the net production of G' while an antagonist draws 
receptor away from the RG complex to the nonproductive IRG complex and results in 
less G. It is experimentally easier to estimate the receptor affinity for G, K1, and the rate 
k9 (relative to k7) in this type of experiment than in an agonist inhibition assay. This is 
because there is only one activation rate constant, one receptor-G protein affinity, and 
one receptor-ligand affinity to consider in the absence of agonist. There is insufficient 
experimental data to estimate these parameters reliably but the data do demonstrate the 
utility of applying the model to this problem. The EC50 for NMS (K6 = 239 pM) was 
determined at two different receptor densities: 1.62 ± 0.27 nM at 4.7 x 10-11 moldm-2 
and 5.2 ± 0.9 nM at 5.1 x 10-11 moldm-2 (both of these concentrations are within the 
linear region for the agonists studied). The line connecting these points on a EC50 vs 
1/[/?0] plot has a slope of -2 x 10-18 mo12dm-5 and an intercept of 44 nM. Using 
Equation 2.A25, k9 is calculated from the intercept to be 183-fold greater than k7. Using 
this value for k9 and the slope, K1 is calculated to be 4.5 x 10-11 moldm-2 from 
Equation 2.A26. 
Stimulation of adenylyl cyclase in the absence of agonist can also be seen in 
Figure 2.1C. Here the action of GDIVS uncouples activation via the RG complex by 
converting most of the active RG complex to inactive RG-GDPOS. This is similar to the 
binding of antagonist (I) which increases the concentration of inactive IRG at the expense 
of RG complex. Agonist-mediated inhibition of adenylyl cyclase was evident in the 
presence of GDPOS because inhibition of cyclase requires only a low concentration of 
activated Gi. The slight shift in EC50i has the same mechanistic origin as the effect of 
different total receptor sites had on EC50i seen in Figure 2.1A. Negative antagonism is 
rationalized differently here than elsewhere (13, 15, 39, 40). Costa et al. (39) suggested 
that the parameter a should be less than unity and applied to the thermodynamic cycle 
involved in the binding of antagonist (I) to the receptor (R). This would predict 60 
heterologous binding of antagonists to the receptor. Their model further suggests that the 
antagonist bound ternary complex is as capable as agonist bound complex in promoting 
coupling to effector systems (IRG = ARG in Scheme 2.2). Antagonists appear to bind all 
sites with equal affinity (41). Based on biophysical characterization the IR and AR 
complexes (Scheme 2.2) appear to be distinguishable states. Far-UV CD spectra of 
detergent-solubilized pm2 mAcChR were indistinguishable in the unliganded versus 
agonist bound states, however, the antagonist bound state contained 4% less a-helix and 
4% more 13-sheet than the unliganded state.4 The model presented here does not consider 
the IRG complex competent to transduce signal via G proteins. Coupling occurs via the 
agonist-bound ternary complex ARG and it is the ability of an agonist to promote the 
formation of this complex over the AR complex that distinguishes a full from a partial 
agonist. 
In summary, this paper describes studies of pm2 mAcChR coupling to effector 
systems in CHO cells. Data for all agonists appeared to be consistent with a two-state 
model that, with appropriate allowances for differences in coupling strength, accounts for 
the different dependencies of EC50 and maximal response on receptor number per cell 
observed for PI stimulation and inhibition of cAMP formation. Ligand binding data 
were not consistent with a simple two-state scheme but agreed well with the 
physiological determinations if a third site, not competent for coupling, was invoked. 
The model can account for partial agonism, negative antagonism, and under favorable 
conditions can be used to experimentally determine the affinity of G proteins for 
receptors. 
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Appendix 
Two-State Model 
Scheme 2.2 describes a simplified two-state system where binding of agonist 
(A), antagonist (/), and G protein (G) to the pm2 mAcChR (R) equilibrate rapidly. The 
activated G protein (G') arises from ARG and RG and is in a steady state during the 
time the response is measured. Effector activation or inhibition is proportional to [G']. 
In the above model, K1K4, and K6 are dissociation constants, k5 and 1c9 are the 
rate constants for agonist dependent and independent G formation, respectively, and k7 
is the rate constant for G' inactivation. KJC2 = K3K4 in this closed thermodynamic cycle. 
The mass balance equations are, 
[G0]= [G]+[G']+[RG]+ [ARG]  (2.A1) 
[RO]=[R]+[AR]+[RG]+[ARG]  (2.A2) 
when [Go] and [R0] are the total G protein and receptor concentrations. Under conditions 
where [A]  [Ao] and [I] = 0, the following relationship holds, 
d[C] 
= k5[ARG] + k9[RG]k7[C]= 0  (2.A3)
dt 
Solving for the steady-state concentration of [G1 gives this quadratic solution. 
2[Go][Ro]lc ([05 + K2k9 )2 
[G,:s  (2.A4) 
(b+ 11b2  4[Go ][Ro ]K42k7 ([A]+ K2 )([05 + K2k9 )2 ([05 + [A]k7 + 1(2k7  K2k9)) 
where 
b =([A]k5 + K2k9)([A]lC4(k7(K3+ [Go ])  [Bo ]( ks  Ic7))± K2K4(k7([Go]+ K1)+[Ro](k7  k9)))  (2.A5) 62 
Where agonist concentration is saturating, [G']=[G'ss]max and the maximum response 
is given by Equation 2.A6; the basal response in the absence of agonist is given by 
Equation 2.A7. 
2k5 [Go ][Ro
[G,:s]max =  (2.A6) 
(k7 (K3 + [GO D [RO i(k5  ))2
k7 (K3 + [Go]) + [RoKk5  1(7) +1+2k7[Ro]([Ro](ks(k7 
1))  2[Go](ks + 1(7)) 
[G,;s1min 
2k9 [G0][R0]  (2.A7) 
k7(1C1 + [Go]) + [Ro](k7 + k9) + V-41(7 (k7 + k9)[G0][Ro] + (k7 (K1 + [G0]) + [Ro](k7 + k9 ))2 
The EC50 value for agonist A is given by the [A] when [G']  = 0.5([G cs]max  [G Ss]min- ) 
+ [G-]min A general relationship for the EC50 cannot be found but asymptotic values at 
extremes of [R0] can be. Ignoring the highest order [G1 terms in the solution of 
Equation 2.A3 results in a simplified solution. 
[Go Po l([05  K2k9) 
(2.A8) 
[q:s kmPlified  [ A 1(k7 (K3 + [Go ])  [R0 ]( k5 + k7))+ K2 (k7(KI + [Go]) ±[Ro](1(7  k9)) 
Simplified minimal and maximal values from Equation 2.A8 are, 
k9[Go][R0] [G's,  =  (2.A9) 
11  1c7  + [Go ])+ LR0  +k9) 
k5N[Rol 
=  (2.A10) 
max  k7 (K3 + [Go 1)  [Ro ](k5 
and the simplified half-maximal value is, 
K2 (k7 (Ki + [Go ])  [Ro ](k7 -4- k9 )) 
EC50  (2.A11) 
k7 (K3 + [GOD+ [Ro  + k7) 
The simplified solutions approximate the general solutions near the extremes of [R0] and 
were used to derive the following relationships. As [R0] approaches infinity a plot of 
EC50 versus 1/[R0] has the following asymptotic values, 63 
EC50 = K2 
k9  (2.Al2) 
k5 
k7 
slope = K1K2  (2.A13)
k5 + k7 
[q, Lin = [Go ]k9  (2.A14)
k7 + k9 
and 
[G.:, Lax  [Go]  k5  (2.A15) 
k5 + k7 
and as [R0] approaches zero the plot plateaus at the value defined by Equation 2.A16 and 
[G cs]miii and [G'ss]max are equal to Equations 2.A9 and 2.A10. 
K1+ [Go]
EC50 = K2  r (2.A16)
K3 + 190 
1 
Equation Al6 simplifies to K4 when [G0] << K1, K3 . 
Negative Antagonism 
Antagonist (I) binds to R and RG with the same affinity and RG gives rise to 
activated G protein with rate constant k9. 
Under conditions where [1]  Vol and in the absence of A the mass balance 
equations are, 
[G0 = [C] + [G] + [RG] + [IRG]  (2.A17) 
[R0 ]= [R] + [/R] + [RG] + [/RG]  (2.A18) 
and assuming that [G1 is at a steady state, 
d[G']  k9 [RG] k7 [G'] = 0  (2.A19)
dt 
Solving for the steady state concentration of [G1 gives, 
2[Go  [Kok92
[G,:s  (2.A20) 
(b + b2  + K6 )(Mk) ± K6 (k2 +k9))) 4[G0 ][Ro ]k7k92 64 
where 
b = k9(k7([0[G0]+[R0]+ KO+ K6 ([G0 [ + K1)) + K6 [Ro ](k7 + k9))  (2.A21) 
Equation 2.A20 predicts that [G '] will decrease from a maximal value at [I] = 0 of, 
2k9[G0][R0]	  (2.A22) 
1c7 (K1 + [Go]) + [Ro](k7 + k9)+ .11-41c7(k7 + k9)[Go ][Ro ] + (k7(Ki + [GO]) + [Ro ](k7 +k9))2 
to zero at saturating [I]. A simplified solution, derived as above, is valid near the 
extremes of [R0]. 
[G0 ][R0 ]K6k9
=	  (2.A23) ]simplified  [I]([ G01±[R0]± K1)± K6(1c7(Ki ±[G0])±[R0}(k7  k9)) 
K6(k7(Ki + [GO]) +[R0](k7  k9)) 
(2.A24) (EC50 )simplified  k7 (K, 1-[Go]+ [Ro]) 
As [R0] approaches infinity a plot of EC50 versus 1/[R0] has an intercept defined by 
Equation 2.A25, a slope by Equation 2.A26, and as [R0] approaches zero the EC50 
plateaus at K6. 
+ k9 
EC50 = K6	  (2.A25) 
1c7 
and 
slope =	  (2.A26) 
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Chapter 31
 
Site-Directed Mutagenesis on the m2 Muscarinic 
Acetylcholine Receptor. The Significance of Tyrosine 403 in 
the binding of agonists and functional coupling 2 
Summary 
The first step in the transmembrane signal mediated by G protein-coupled 
receptors is binding of agonist to receptors at the cell surface. The mechanism of the 
resulting receptor activation is not clear, but models based on the ternary complex model 
are capable of explaining most of the observations that have been reported in G protein-
coupled receptors. This model suggests that a single agonistreceptorG protein 
complex capable of activating G protein is formed as the result of agonist binding. 
Extensions of this basic model differ primarily in whether an equilibrium between active 
and inactive conformations is required to explain experimental results. We report results 
on ligand binding and coupling to physiological effector systems of the m2 muscarinic 
acetylcholine receptor site-directed mutant Y403F expressed in Chinese hamster ovary 
cells and compare our results with results reported for the homologous Y506F mutation 
in the m3 muscarinic receptor (Wess, J., Maggio, R., Palmer, J. R., and Vogel, Z. 
(1992) J. Biol. Chem. 267:19313-19319). The mutation in the m2 muscarinic receptor 
reduced absolute agonist affinities more dramatically than in the m3 muscarinic receptor. 
1This chapter is a forthcoming paper in Molecular Pharmacology © 1997 by The American Society 
for Pharmacology and Experimental Therapeutics, and is reprinted with permission. 
2This work was supported by the National Institutes of Health Grants HL23632 and ES00210. 
Abbreviations: CHO, Chinese hamster ovary; G protein, guanine nucleotide-binding protein; KL, 
KM, and Kii, the low, medium, and high affinity equilibrium dissociation constants, respectively; 
NMS, S- ( )- N- methylscopolamine; QNB, R-()-quinuclidinyl benzilate; Y403F, residue 403 
mutated from tyrosine to phenylalanine. 69 
Unlike the results reported for the m3 subtype mutant, where coupling to physiological 
effector systems was reduced, coupling to effector systems for the mutant in the m2 
subtype was robust. In the Y403F m2 muscarinic receptor the difference between the 
two agonist binding affinities was greater than in the wild-type receptor while in the m3 
subtype the effect of the mutation was to decrease this difference. A prediction of the 
ternary complex model is that relative binding affinities will affect the steady-state 
concentration of the agonistreceptorG protein complex and as the result the extent of G 
protein coupling. These results can best be rationalized by this model, which suggests 
that the activation of G protein-coupled receptors is achieved by the relative affinity of 
agonist for two receptor states and does not require the existence of multiple states in 
conformational equilibrium. 
Introduction 
Muscarinic acetylcholine receptors are members of a diverse group of receptors 
and sensory proteins that are characterized structurally by a pattern of hydrophobic 
residues suggesting seven transmembrane domains, and functionally by coupling the 
binding of an extracellular activator to intracellular effector via G proteins. Five 
muscarinic receptor subtypes (ml m5) have been cloned and expressed (1-5). The odd-
numbered subtypes couple preferentially to the stimulation of phospholipid metabolism 
and the even-numbered subtypes couple preferentially to the inhibition of cAMP 
formation. The m2 subtype is widely distributed in mammalian tissue and is the only 
subtype found in mammalian heart (3), where it acts via the cardiac pacemaker cells to 
activate inwardly-rectifying potassium channels in addition to the inhibition of adenylyl 
cyclase and stimulation of phospholipid metabolism (6). Two results of agonist binding 
to the cardic m2 muscarinic receptor are a decrease in heart rate, due to the activation of 
inwardly-rectifying potassium channels, and a decrease in the force of contraction, due to 
the reduction in voltage-gated calcium currents regulated indirectly via cAMP levels (7). 70 
The agonist binding site of G protein-coupled receptors is thought to lie in the 
transmembrane bundle of amphipathic a-helices. Photochemical cross-linking with an 
analog of 11-cis-retinal predominantly labeled the third and sixth transmembrane helices 
suggesting that they make up part of the retinal binding site of rhodopsin (8). Among G 
protein-coupled receptors that bind biogenic amines a conserved aspartate residue in the 
third transmembrane helix is critical for the binding of ligand (9-11). We report results 
from the site-directed mutant Y403F in the m2 muscarinic receptor, located in the sixth 
transmembrane helix one residue beyond a highly conserved proline. Results from the 
13-adrenergic (12) and bradykinin (13) receptors where the homologous residue is a 
phenylalanine and from the m3 muscarinic receptor (14, 15), rhodopsin (16), and the 
neurokinin-2 receptor (17) where the homologous residue is a tyrosine suggest that these 
residues are part of or near the agonist/retinal binding sites of these G protein-coupled 
receptors. 
The nature of the relationship between agonist binding to G protein-coupled 
receptors and the activation of G proteins is poorly understood. Models of G protein 
activation differ in the number of states of the receptor. The simplest models rely on two 
receptor states with respect to agonist and G protein binding (scheme in Figure 3.1). 
Agonist binds free receptor and G protein-complexed receptor that have different agonist 
affinities, and G protein binds free receptor and agonist-complexed receptor that have 
different G protein affinities. This ternary complex model results in two G protein­
complexed states: the receptorG protein binary complex and the agonistreceptorG 
protein ternary complex. G protein activation occurs via the ternary complex (18, 19) or 
via both the binary and the ternary complexes at different rates (20). The basic model 
was extended to explain a constitutively active D-adrenergic receptor mutant (21), 
negative antagonism (22), inverse agonist activity (23), and these extensions have been 
generalized into the cubic ternary complex model where each state represented in the 71 
scheme in Figure 3.1 is proposed to exist in an active and inactive conformation. These 
models describe G protein-coupled receptors as existing in multiple states of activity 
where agonists promote the more active state and inverse agonists promote the less 
active state by mass action. The simpler model suggests that agonists activate G protein-
coupled receptors by occupancy. The binding of agonist to the two linked states of the 
receptor results in greater concentrations of the agonistreceptorG protein complex as 
the ratio of agonist affinities increases and is a measure of intrinsic efficacy of an agonist 
in a given receptor/G protein system (19). Here efficacy is defined as the ability of an 
agonist to promote a physiological response independent of the absolute affinity of the 
agonist for the receptor. 
The difference between the above models is whether receptor occupancy, and 
therefore the maintenance of a steady-state concentration of agonistreceptorG protein 
complex, is the primary mode of receptor activation. The alternative is that a 
conformational equilibrium between active and inactive receptor states plays the primary 
role and receptor occupancy plays a secondary role. The choice of model has a practical 
consideration in the drug design process in the attention paid to agonist-receptor binding 
characteristics. 
The m2 muscarinic receptor expressed at high levels in CHO cells is an 
especially well suited system for the evaluation of models of G protein-coupled receptors 
because the agonist affmities are well separated and clearly defined in competition 
binding assays. A relationship between the ratio of agonist affinities in muscarinic 
receptors and apparent efficacy was first reported by Birdsall et al. (24). Our results 
identify a specific tyrosine residue that is important for agonist binding in the m2 
muscarinic receptor. Similar but less dramatic effects on agonist binding were reported 
for the homologous mutation in the m3 muscarinic receptor (14, 15). Unlike the results 
in the m3 subtype where mutating this tyrosine resulted in diminished coupling to 72 
Figure 3.1. Ternary complex model describing the binding of agonist and G 
protein to G protein-coupled receptors. A is agonist, G is G protein, R is the free 
receptor, AR is the agonist bound receptor, RG is the G protein bound receptor, and ARG 
is the agonistG proteinreceptor ternary complex. 
effector systems, this mutation in the m2 subtype resulted in increased coupling. The 
effects of these mutations correlate with changes in the ratio of agonist affinities for RG 
compared to R (scheme in Figure 3.1) that increase in the m2 subtype but decrease in the 
m3 subtype. The correlation of decreased agonist affinity with decreased coupling to an 
effector system led Wess et al. (15) to conclude that this tyrosine is part of a binding 
and trigger mechanism in the m3 subtype serving both in agonist binding and in the 
activation of G proteins. We argue against this explanation of the results for the m3 
mutation and suggest that the ternary complex model provides an adequate explanation 
of the results from both subtypes. 
Materials and Methods 
The procedures used to produce stably transfected clonal CHO cell lines 
overexpressing wild-type and mutant receptor (2) and enriched membrane preparations 
(25, 26) were previously described. 73 
Materials 
[41]()NB, [3H]NMS, and [14C]cAMP were purchased from DuPont NEN, 
[3H]adenine and [3H]myo- inositol from American Radio labeled Chemicals, 
acetylcholine from Sigma, carbachol and pilocarpine from Aldrich, oxotremorine M 
from Research Biochemicals, Ro 20-1724 from Biomol, and guanylyl­
imidodiphosphate from Boehringer Mannheim. 
Site-directed mutagenesis 
The Y403F mutant porcine m2 muscarinic receptor was produced by 
oligonucleotide-directed mutagenesis by the method of Vandeyar et al. (27) except that 
E. coli ER1451 was used. The mutation was introduced by priming second strand 
synthesis with the antisense oligonucleotide: 5'- ATGACGTTGAACGGGGCCCAA -3' 
(the base change is underlined). The wild-type coding region was ligated into M13mp18 
as a HindlIIIEcoRI fragment derived from the pSVE expression vector (2) kindly 
provided by Dr. Daniel Capon, Genentech. The sequence of the Y403F was confirmed 
by dideoxy sequencing (28). The mutated coding region was ligated into the pSVE 
expression vector and used to transfect CHO cells. 
Effector Coupling 
Phosphatidylinositol stimulation was determined in attached CHO cells 
expressing Y403F muscarinic receptor plated at 2 x 104/mm2 and incubated in 4 pCi/m1 
[3H]myo-inositol for 72 h. Agonists were added and inositol 1-phosphate accumulation 
was measured after 30 min at 37 °C as described by Lee et al. (29). Inhibition of 
forskolin-stimulated adenylyl cyclase activity was determined in attached confluent CHO 
cells in the presence of 100 pM isobutylmethylxanthine, 50 pM Ro 20-1724, and agonist 
after exposing the cells to 8 ilCi/m1 [3H]adenine for 2-3 h. The 20 min assay at 37 °C 
was started by the addition of 40 pM forskolin and [3111cAMP was determined 74 
according to the method of Salomon (30). Results for Y403F mutant and wild-type were 
compared at similar levels of expression in cloned cells lines. 
Ligand binding 
Ligand binding to enriched membrane preparations was assessed in 10 mM 
HEPES, 5 mM MgC12, 1 mM EDTA, 1 mM EGTA, pH 7.4 at 25 °C. After 4-6 h 
samples were filtered through Schleicher & Schuell #32 glass-fiber filter membranes 
pretreated with 0.1% (w/v) polyethylenimine on a Brandel Harvester (Gaithersburg, 
Maryland) and washed with approximately 10 ml ice-cold 50 mM sodium phosphate, 
1 mM EDTA, pH 7.4. Nonspecific binding was assessed in the presence of 1-4 x 104 
fold excess unlabeled ligand. In direct binding experiments on the Y403F mutant the 
receptor site concentration was 140-350 pM ([3H]NMS) and 60-110 pM ([3H]QNB). 
In competition binding experiments with [3H]NMS (2.5-6.5 nM) the receptor site 
concentration was 60-390 pM. 
Protein stability 
Resistance to thermal inactivation was assessed in enriched membrane 
preparations in the presence and absence of saturating [3H]QNB. Membranes were 
exposed to different temperatures for 1 h and quenched on ice and residual [3H]QNB 
binding was determined. 
Data Analysis 
Functional assays were fit to Equation 1, where [x] is the agonist concentration, 
max1,2 are the maxima of the inhibitory and stimulatory portions of the curve, min is the 
minimum of the curve, and p1,2 are the respective slope factors. For adenylyl cyclase 
assays that showed only an inhibitory phase the first two terms were used and for assays 
of phosphatidylinositol metabolism stimulation the first and last terms were used. 75 
max  min  max2  min CPM = min +  (1) p1  p2
[x]  r(Ec50) 1
(EC50i)  [x]  ) 
In direct saturation binding experiments total bound radioligand was analyzed as 
the sum of specific, [RL], and nonspecifically, N[L], bound ligand according to the 
quadratic solution of Equation 2 and Equation 3 where [Rd and [Lo] are the total 
receptor and ligand concentrations, K is the equilibrium dissociation constant and N is 
the proportionality constant of nonspecifically bound ligand to free ligand concentration. 
Po] [Rn)([4]  [RL]) [Rn =  (2)
K(N +1) 
N([4]  [R11)
N[L] =  (3)
N + 1 
Agonist binding was assessed in competition with radiolabeled antagonist. 
Agonist binding data were fit to two or three noninteracting classes of sites that bound 
antagonist with the same dissociation constant. Total labeled antagonist specifically 
bound, [RU], is the sum of that bound at each subclass of agonist binding sites according 
to the polynomial solutions of Equation 4,3 
Fi[R011,01[Rn)
[Rn=  (4) 
1-1 K(N + 1)(1 +V)+ [Lo] [Rn 
where [Ro] equals the total concentration of receptor, Fi is the fraction of [R0] in site i, 
[L0] is the total labeled antagonist concentration, [A] is the total agonist concentration 
(equal to the free concentration since no displacement occurs until [A] > {Rd), K is the 
dissociation constant for radiolabeled antagonist, and Ki is the dissociation constant for 
the agonist at site i (referred to as KH, KM, and KL, the high, medium, and low affmity 
3Expanded solutions of these equations appear in the Appendix to this dissertation. 76 
constants).2 Data were fit by nonlinear least-squares procedures using Marquardt's 
algorithm (31) and parameter values are reported as the mean and 95% confidence 
interval of several determinations. 
Ligand binding energetics 
The difference in ligand binding energy between Y403F mutant and wild-type 
muscarinic receptor was calculated with Equation 5, 
A(AG°) = AG°mutant AG°Wild type = RT ln(Kmutantl Kwildtype)  (5) 
where AG° is the standard Gibbs free-energy change, R is the gas constant, T is the 
absolute temperature, and K is the equilibrium dissociation constant. A(AG°) is the 
apparent binding energy contributed by the tyrosine hydroxyl (32); it does not take into 
account the changes in solvation of the mutant receptor or potential changes in receptor 
stability. A(AG°) is defined such that positive values indicate that the mutant binds 
ligand less strongly. 
Results 
Ligand binding properties of Y403F m2 muscarinic receptor were assessed in 
sucrose gradient enriched membrane preparations. Antagonists [3H]NMS and [3H]QNB 
bound to a single class of sites with affinities that were 2.5- and 1.7-fold lower than 
wild-type receptor. Agonists appeared to bind to two classes of sites, compared to three 
for wild-type, with affinities (KM values) that were 200-300-fold lower for acetylcholine 
and carbachol than wild-type. The binding affinities for the agonists oxotremorine M and 
pilocarpine were less dramatically affected being reduced by less than 100-fold (Table 
3.1). Competition binding assays were conducted in the presence and absence of 
guanylyl-imidodiphosphate, a nonhydrolyzable analog of GTP; results for carbachol are 
shown in Figure 3.2. Data in the presence and absence of guanine nucleotide were fit so 
that values for KH and KM were shared in the analysis of a given experiment (20). The 77 
highest affinity site, Kll, was sensitive to the presence of guanine nucleotide, consistent 
with binding to the G protein-receptor complex. 
Among G protein-coupled receptors, agonists can be characterized by their 
affinity for free receptor and by their ability to promote the formation of the agonist 
receptorG protein ternary complex over the agonistreceptor binary complex. Agonist 
affinity for free receptor is quantified by KM values while the ability to promote the 
ternary complex is described by the parameter a (19, 20) which is calculated as the 
quotient of KM and Kll values (Table 3.1). The a values for Y403F were approximately 
4, 2, 3, and 0.6 times greater than for wild-type receptor for acetylcholine, carbachol, 
oxotremorine M, and pilocarpine, respectively. 
When comparing a mutant and wild-type protein it is difficult to attribute 
differences in ligand affinity to a specific interaction between the mutated residue and the 
ligand if the mutation also results in altered protein structure. Resistance to irreversible 
thermal inactivation in the presence and absence of the antagonist QNB was used to 
assess the effects of the mutation on m2 muscarinic receptor structure. Y403F was 
indistinguishable from wild-type receptor in its resistance to thermal inactivation 
suggesting that loss of the tyrosine hydroxyl did not significantly destabilize receptor 
structure (Figure 3.3). 
Functional coupling of the mutant receptor was assessed in attached tissue culture 
cells and the results compared to data for wild-type receptor at similar expression levels 
(20). Acetylcholine, carbachol, and oxotremorine M stimulated phosphatidylinositol 
metabolism to a slightly greater extent than wild-type while the EC50 values were greater 
than wild-type by 150, 120, and 40, respectively (Table 3.2). These increases in EC50 are 
similar to the increase in KM values: 290, 180, and 65, for acetylcholine, carbachol, and 
oxotremorine M, respectively (Table 3.1). The values of KM and the EC50 for 
stimulation of phosphatidylinositol metabolism were found to be approximately equal 78 
for the wild-type receptor and this was rationalized as coupling via a G protein that has a 
relatively low affinity for the receptor (20). The mutant receptor appeared to stimulate 
phosphatidylinositol metabolism to a greater extent than wild-type with acetylcholine, 
carbachol, and oxotremorine M but in six experiments pilocarpine failed to stimulate 
phosphatidylinositol metabolism significantly (Table 3.2). 
Acetylcholine, carbachol, and oxotremorine M inhibited cAMP formation to an 
extent indistinguishable from wild-type while pilocarpine inhibited cAMP formation less 
than wild-type at comparable receptor densities. The EC50 for adenylyl cyclase inhibition 
was inversely dependent on the receptor density as was found for wild-type (20) and the 
slope of this relationship was greater than that for wild-type, consistent with the observed 
two orders of magnitude lower affinity of agonists for the receptor (Table 3.3). The 
relationship between the EC50 for adenylyl cyclase inhibition and the affinity of agonists 
for the receptor is more complicated than the relationship between EC50 for stimulation 
of phosphatidylinositol metabolism and agonist affinity (20), making a comparison of 
EC50 differences and affinity differences more difficult. The limiting slope and intercept 
of these plots are interpretable in terms of simple relationships as was done with wild-
type (20). However, the lower agonist affinity observed with the Y403F mutant requires 
that receptor sites density be greater for the mutant than for wild-type to allow a similar 
analysis. The experimentally accessible range of receptor concentrations was less than 
that available for wild-type and this type of analysis was not possible. 
Discussion 
Substituting phenylalanine for the conserved tyrosine in the sixth transmembrane 
helix appears to meet the general criteria of a nondisruptive deletion (34). The mutation 
removes a side chain functional group that is involved in a specific interaction and 
replaces it with a smaller group that does not appear to be involved in overall structural 
stability. The calculated A(AG°) values of approximately 0.5 kcal/mol for antagonists Table 3.1. Ligand binding properites of Y403F mutant and wild-type m2 muscarinic receptor.Values are the weightedmean ± 
95% confidence interval; the number of experimental determinations are indicated in parentheses. A(AG°) values are presented ± 
95% confidence interval. 
Y403F  Wild-type  A(AG°) (kcal-morl) 
Antagonists  K (pM)  K (pM)  Kb 
[3H]NMS  630 ± 240 (5)  253 ± 45 (15)  0.54 ± 0.22 
[3H]QNB  29.3 ± 3.4 (3)  17.4 ± 2.8 (16)  0.31 ± 0.10 
act Agonists  KH (nM)  KM (1.1M)  KH (nM)  KM (11M)  KT, (NM)  as  K Hb  K b m 
acetylcholine  107 ± 51(3)  101 ± 36 (4)  950 ± 560  1.45 ± 0.49  0.350 ±  11.1 ± 3.9  240 ± 100  2.55 ± 0.25  3.36 ± 0.21 
(12)  0.087 (15)  (13) 
carbachol  390 ± 170 (5)  248 ± 68 (5)  630 ± 320  3.6 ± 0.80  1.37 ± 0.16  21.7 ± 3.7  380 ± 100  2.77 ± 0.26  3.08 ± 0.16 
(19)  (38)  (37) 
oxotremorine M  51 ± 43 (5)  25.8 ± 4.5 (5)  500 ± 430  2.16 ± 0.89  0.40 ± 0.14  13.0 ± 8.2 (9)  190 ± 100  1.88 ± 0.49  2.47 ± 0.22 
(10)  (16) 
pilocarpine  2370 ± 680  149 ± 52 (7)  63 ± 29  27 ± 17 (8)  2.78 ± 0.73  25 ± 16 (9)  100 ± 70  2.65 ± 0.39  2.36 ± 0.24 
(6)  (14) 
as is calculated as the quotient of the parameters KM and KH. Indicates the equilibrium  constant for which the A(AG°) values are calculated. 80 
Figure 3.2. [3H]NMS displacement by carbachol in Y403F CHO cell membranes. 
Data were fit to two independent classes of sites, described in Materials and Methods. 
The parameter values for the fitted lines are shown ± asymptotic standard errors. KH = 
0.64 ± 0.14 pM, KM = 238 ± 9 pM, FH = 39.9 ± 1.4% in the absence of guanylyl­
imidodiphosphate ( ), and 13.6 ± 2.0% in the presence of 200 pM guanylyl­
imidodiphosphate (0 ). Inset, [3H]NMS binding to the same membrane preparation 
presented as a Scatchard plot (33) K = 813 ± 29 pM. The concentration of [3H]NMS 
for the carbachol competition was 5.7 nM and the receptor site concentration for both 
the competition and the direct binding of [3H]NMS was 190 pM. '11 1­
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Figure 3.3. Irreversible thermal inactivation of Y403F m2 muscarinic receptor. 
Experiments were done in the absence (0 ,  ,  A) and presence ( ,  ,  ) of 
saturating antagonist [3H]QNB. The TO 5s were 51.8 ± 1.0° (n = 3) in the absence and 59.1 
± 1.8° (n = 3) in the presence of saturating QNB. The horizontal bars represent the mean 
and 95% confidence interval of results from wild-type receptor, 54.1 ± 1.6° (n = 15) in the 
absence and 60.2 ± 1.3° (n = 16) in the presence of saturating QNB. These differences 
were not significantly less than wild-type (P = 0.05). QNB stabilized the receptor by 7.3 ± 
1.3° in a paired sample analysis, a value not significantly different from wild-type (6.2 ± 
0.9°). 83 
Table 3.2. The effect of Y403F mutation on phosphatidylinositol stimulation in 
whole cell assays. Values for EC50 and fold maximal stimulation of 
phosphatidylinositol metabolism are shown for the indicated receptor site densities. 
These values are compared to the wild-type values for the same range of receptor site 
densities observed in wild-type expressing CHO cells, from data previously published 
(20). Results with pilocarpine were not significant. 
Agonist  n  EC50  Fold  [R] (pmol  Wild-type  Wild-type Fold 
(.tM)  Stimulationa  .dm -2)  EC50 (NM)  Stimulation 
acetylcholine  2  60 ± 4  1.6-2.6  1.3-5.0  0.4 ± 0.2  1.2-1.4 
carbachol  4  140 ± 70  2.4-3.0  5.0-33  1.2 ± 0.5  1.6-2.4 
oxotremorine M  2  40 ± 3  1.6-2.6  1.3-5.0  1.0 ± 0.5  14-1.5 
pilocarpine  6  ns  ns  0.7-10.8  10 ± 4  1.1-1.3 
aFold maximal stimulation increased with increasing [R] as in wild type. EC50 values are presented 
± standard deviation. 
Table 3.3. The effect of Y403F mutation on adenylyl cyclase inhibition in whole cell 
assays. EC50 values for the inhibition of adenylyl cyclase activity are reported as a range 
that varies inversely with [R]. Maximal inhibition is reported as mean ± standard 
deviation except for pilocarpine where inhibition was variable and increased with 
increasing [R] as in wild type. These values are compared to the wild-type values for the 
same range of receptor site densities observed in wild-type expressing CHO cells, from 
data previously published (20). 
Agonist  n  EC50  Inhibition  [R] (pmol  Wild-type  Wild-type 
EC50 (04)  Inhibition (%) (PM)  (%)  dm2) 
acetylcholine  3  1.7-4.9  71.3 ± 4.9  5.0-17  0.014-0.07  80.0 ± 3.6 
carbachol  6  1.3-37  70.8 ± 5.1  5.0-33  0.036-0.5  65.4 ± 5.1 
oxotremorine M  5  0.6-4.9  74.4 ± 3.7  5.0-23  0.0087-0.28  76.2 ± 2.5 
pilocarpine  4  10-110  19-43  5.0-23  3.4-15  37-62 84 
and 2.5 kcal/mol for agonists are consistent with the elimination of a hydrogen bond in 
the ligand bound mutant receptor state that exists in the wild-type receptor (Table 3.1) 
(32). An alternative explanation for the role for this tyrosine is as part of an aromatic 
cation -it binding site for the ligand amine, as was proposed based on molecular 
modeling (35). Since tyrosine is predicted to be a stronger locus of cation -it binding 
potential than phenylalanine due to the negative electrostatic potential of the hydroxyl 
oxygen (36) the distinction between the tyrosine hydroxyl being involved in a hydrogen 
bond or contributing negative electrostatic potential to a cation -1t site is not possible with 
the available data. The absence of high resolution structures of the receptor and receptor 
ligand complexes necessarily limits any interpretation. A reasonable explanation of these 
data is that the tyrosine hydroxyl in muscarinic receptors forms a hydrogen bond, the 
strength of which is important to the binding of the native agonist acetylcholine. 
Results presented here and elsewhere (14) confirm the importance of tyrosine 
residues in the binding of agonists, especially the native agonist acetylcholine and its 
close analog carbachol, and their relative unimportance in the binding of antagonists. The 
contrast between the importance of this tyrosine residue in agonist and antagonist 
binding suggests a role for this residue in the mechanism of receptor activation of G 
proteins since its absence in m3 muscarinic receptor was coincident with a negative 
effect on receptor activation. Wess et al. (1992) proposed such a role for the conserved 
tyrosine in the sixth transmembrane helix of the m3 muscarinic receptor while results 
presented here suggest little or no role in receptor activation of G proteins for this residue 
in the m2 muscarinic receptor. 
Site-directed mutagenesis of each of four transmembrane tyrosine residues in the 
m3 muscarinic receptor resulted in receptors with decreased affinity for acetylcholine and 
carbachol. The largest decrease in agonist affinity among these tyrosine mutants occurred 
at residue 506, 58- and 27-fold for acetylcholine and carbachol, respectively, while 85 
antagonist affinities were reduced only a few fold (15). We mutated the homologous 
residue in the m2 muscarinic receptor, tyrosine-403, and found that antagonist affinities 
decreased by twofold but agonist affinities were decreased by approximately 280- and 
180-fold for acetylcholine and carbachol. In contrast to the results from the m3 
muscarinic receptor functional coupling, the inhibition of adenylyl cyclase did not appear 
to be affected beyond that expected from the decrease in receptor affinity for 
acetylcholine and carbachol. Stimulation of phosphatidylinositol metabolism was 
affected consistent with the decreased agonist affinity while the maximal response was 
greater than wild-type at comparable receptor densities. 
The scheme in Figure 3.4 is an extension of the ternary complex equilibrium 
binding model (Figure 3.1) to take into account coupling via both the agonistreceptor 
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Figure 3.4. Ternary complex model with kinetic pathways toward G protein 
activation and inactivation. G' is the activated G protein, see legend to Figure 3.1 for 
explanation of receptor states pictured. 86 
binary complex and the agonistreceptorG protein ternary complex (20). The model 
describes the effect of G protein-coupled receptor activation on the steady-state 
concentration of activated G protein (G') as a function of agonist, receptor, and G 
protein concentrations, the affinities for each of these for each other, and the rate 
constants for G protein activation and inactivation. If effector coupling is proportional to 
activated G protein concentration then the model describes the effect of G protein-
coupled receptor activation on effector coupling. The model predicts a pattern of behavior 
for the two parameters observable in effector coupling assays, the maximal response and 
the concentration of agonist that produce a half-maximal response (EC50). As receptor 
density increases maximal response increases while the EC50 is unchanged, and equal to 
the lower affinity agonist dissociation constant, until G protein concentration becomes 
limiting. When G protein concentration is limiting, further increase in receptor 
concentration has no effect on maximal response but the EC50 decreases as less agonist 
is required for a given response. Between the extremes of limiting receptor concentration 
and limiting G protein concentration both parameters are predicted to vary with varying 
receptor density. The placement, breadth, and shape of this transition depend on the 
receptorG protein affinity and the ratio of the agonistreceptorG protein affinity and 
the agonistreceptor affinity (a parameter referred to as a). 
The scheme in Figure 3.4 explained the observed effects of variable cell-surface 
receptor density on effector coupling in m2 muscarinic receptor expressing CHO cells 
(20). The EC50 of the inhibition of adenylyl cyclase was found to be inversely 
proportional to receptor density while the maximal response was constant with varying 
receptor density for full agonists acetylcholine, carbachol, and oxotremorine M. 
Pilocarpine displayed the same effect of receptor density on EC50; the maximal effect 
however was reduced relative to the other agonists (partial agonism) at the low end of the 
receptor density range examined and was indistinguishable from the other agonist effect 87 
at the high end of receptor density. In contrast the EC50 for the stimulation of 
phosphatidylinositol metabolism was constant and approximately equal to the KM 
binding constant for each agonist, with varying receptor density but the maximal 
response increased with receptor density. The different pattern of behavior of the two 
effector coupling systems over the same receptor density range was rationalized as the 
muscarinic receptor coupling to adenylyl cyclase via a relatively high-affinity G protein 
and coupling to phosphatidylinositol metabolism via a relatively low-affinity G protein. 
The model rationalized the partial agonism observed with pilocarpine and the negative 
antagonist observed with QNB, NMS, and hyoscyamine in adenylyl cyclase assays. 
The pilocarpine results in the Y403F mutant differ from the other agonists in two 
respects that have interpretable significance on the effects of the Y403F mutation. The a 
values, a measure of intrinsic efficacy, calculated from data in Table 3.1 were found to be 
greater than wild-type for acetylcholine, carbachol, and oxotremorine M but less than 
wild-type for pilocarpine. The maximal response observed in both physiological assays 
for pilocarpine was less than that found for wild-type at comparable receptor density, 
while the response found with acetylcholine, carbachol, and oxotremorine M was the 
same or better than wild-type. The a value is related to the ability of an agonist to 
produce a physiological response since it is a measure of the ability of the agonist to 
promote the formation of the agonistreceptorG protein complex at the expense of the 
agonistreceptor complex. The predicted effect of these changes in a values is that the 
maximal response in physiological assays would be equal to or greater than wild-type 
for acetylcholine, carbachol, and oxotremorine M and equal to or less than wild-type for 
pilocarpine. 
Not included in the scheme in Figure 3.4 are possible effects of multiple G 
proteins, coupling via a and 13y G protein subunits, or multiple active conformational 
states that are differentially stabilized by agonist. In addition, differences between the 88 
wild-type and Y403F clonal cell lines in G protein concentration or in the ratio of 
multiple G proteins or mutational alterations in the composite rate constant for G protein 
activation would be expected to affect the maximal response. The effect of a change in a 
value on maximal response is predicted to be sensitive to differences in the affinity of the 
receptor for G protein such that an effect visible in one assay may not be visible in 
another if it was coupled via a different G protein. The same effect can be explained by a 
single G protein activating via a and fry G protein subunits. This would require 
expanding the model in Figure 3.4 at the composite activation steps to include separate 
activation routes and different subuniteffector concentration dependencies. 
The change in single G protein concentration or ratio of G proteins that act 
similarly or in the composite rate constant for G protein activation cannot explain our 
results since they would affect the maximal response to a similar extent for all agonists 
and would affect the inhibition of cAMP formation and the stimulation of 
phosphatidylinositol metabolism similarly. Results from a reconstituted system of 
purified m2 muscarinic receptor and Gi indicated that pilocarpine and carbachol 
promoted GTPase activity similarly (37) suggesting that if multiple active conformations 
that activate G protein agonist-specifically exist they are not significant in wild-type, 
however, this may not be true for the Y403F mutant. The cell lines used for these studies 
contain a mixture of Gi2 and Gi3, Gil and Go are not present3 which limits the potential 
for changes in G protein ratio having a differential effect on the wild-type and mutant 
expressing cell lines. Differential effects of O'y subunit stimulation of phospholipase C 
appear unlikely in two respects. This effect would require agonist-specific stimulation of 
G proteins in the mutant that is not observed in wild-type. If this occurred in our 
experiments then the differential mixture of fry subunits that might result would have to 
3J. Robishaw, unpublished data 89 
have a differential effect on phospholipase Cr3 isozymes. Recent results with 
phospholipase CI33 indicate that there is little difference in the potencies among different 
fry subunits, apart from the very low activity of 13171, (38). While there are many 
factors, some difficult to control for, that have the potential to complicate the 
interpretation of the results, the simplest explanation is that the observed agonist-specific 
change in a value between wild-type and the mutant receptor is the best explanation of 
the agonist-specific changes observed in functional assays. 
The Y403F mutation in m2 muscarinic receptor appears to have affected only the 
ligand binding affinities of the receptor. Our data are consistent with this tyrosine 
hydroxyl being involved in a hydrogen bond important in the stability of the agonist 
bound state. This tyrosine also appears to be more important in the free receptor than in 
the G protein associated receptor state for acetylcholine, carbachol, and oxotremorine M. 
Effects observed in physiological assays can be explained by reductions in the absolute 
receptoragonist affmity and the relative affinity of agonists for the free receptor and the 
receptorG protein complex. 
These results help explain an otherwise difficult to rationalize result from 
mutagenesis experiments on the proline residue in the sixth transmembrane domain of 
the m3 muscarinic receptor. This proline is one residue away from the tyrosine and is 
conserved in virtually all G protein-coupled receptors (the major exception being the 
olfactory receptors). If the tyrosine is part of a binding and trigger mechanism for G 
protein activation, as was suggested (15), then it seems reasonable to expect that the 
adjacent proline, with its conformational flexibility, is also an integral part of the trigger. 
Support for this model can be found in the results of molecular dynamics simulations on 
the transmembrane segments of 5-hydroxytryptamine receptor that suggested agonist 
but not antagonist binding would result in large movements in the transmembrane 
helices five and six (39). A trigger mechanism of receptor activation suggests that the 90 
agonistreceptorG protein complex can assume an active and inactive conformation. 
However, mutating this proline residue in the m3 muscarinic receptor had no effect on 
antagonist binding, little effect on agonist binding, and no effect on its ability to stimulate 
phosphatidylinositol metabolism (40). In the Y403F m2 muscarinic receptor agonist 
binding to the higher affinity G protein-coupled receptor state was sensitive to guanine 
nucleotides and the mutant receptor was capable of eliciting a functional response similar 
to wild-type, while in the Y506F m3 muscarinic receptor (15) agonist binding was not 
sensitive to guanine nucleotides and the mutant receptor was less capable than wild-type 
of eliciting a functional response. This lack of sensitivity to guanine nucleotides in the 
m3 subtype mutant suggests a relative decrease in a values for acetylcholine and 
carbachol where in the m2 subtype the values increase. An explanation of the results 
from the m3 muscarinic receptor is that, as in the m2 muscarinic receptor, the conserved 
tyrosine residue is primarily involved in an interaction that stabilizes the agonist bound 
state; its reduced ability to stimulate phosphatidylinositol metabolism having the same 
mechanistic origin as a similar effect seen only with pilocarpine in the m2 subtype. There 
is no reason to believe that a single mutation could not have multiple effects but the data 
suggest that these mutations in or near the putative agonist binding site effect only 
binding. The trigger mechanism, if it exists at all, lies elsewhereperhaps involving the 
seventh transmembrane helix, as the proline in that helix had the most dramatic effect on 
coupling in the m3 subtype (40). 
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Chapter 4
 
The Role of Aspartate 69, 97, and 103 in Ligand Binding and
 
Signal Transduction of the m2 Muscarinic Acetylcholine
 
Receptor. A Site-Directed Mutagenesis Study'
 
Summary 
To understand the role of the conserved aspartate residues in the second and 
third transmembrane domains of the porcine m2 muscarinic acetylcholine receptor, 
these residues were mutated individually and in pairs to asparagine and stably 
expressed in Chinese hamster ovary cells. D69N (helix 2) eliminated high affinity 
guanine nucleotide-sensitive agonist binding for acetylcholine, carbachol, 
oxotremorine M, and pilocarpine. Coupling of acetylcholine, carbachol, and 
pilocarpine to adenylyl cyclase inhibition and phospholipase C stimulation were 
eliminated but oxotremorine M was partially activite. Pertussis toxin-insensitive 
adenylyl cyclase stimulation was only observed with acetylcholine and carbachol, 
although at lower levels than seen for wild-type receptors. This altered agonist-specific 
G protein coupling is explained by three active receptor conformational states. D97N 
(extracellular end, helix 3) reduced ligand affinity; i(AG °) values were approximately 
1 kcal/mol for agonists and slightly less for antagonists. Agonist-promoted functional 
activity was similar to wild-type in extent and altered in EC50 consistent with the 
'This work was supported by the National Institutes of Health Grants HL23632 and ES00210. 
The abbreviations used are: DxN, an aspartate to asparagine mutation where the number x indicates the 
position that mutation was introduced; Dx.yN, an aspartate to asparagine double mutant where x and y 
indicated the two positions that mutations were introduced; CHO, Chinese hamster ovary; G protein, 
guanine nucleotide-binding protein; Kb KM, and KH, the low, medium, and high affinity equilibrium 
dissociation constants, respectively; Gpp(NH)p, guanylyl-imidodiphosphate; hyoscyamine, S -( )­
hyoscyamine; NMS, S-()-N-methylscopolamine; QNB, R-()-quinuclidinyl benzilate. 96 
reduced agonist affinity. Due to poor expression D103N (helix 3) was characterized in 
better expressed double mutants. The D103 anion appeared to contribute 3-6 kcal/mol 
of binding energy to the stabilization of agonistreceptor complexes. Typical results 
from mutating the homologous residue in amine-binding G protein-coupled receptors is 
that functional activity is preserved with EC50s that are affected, consistent with the 
dramatically reduced agonist affinity when mutant receptors are expressed at 
appropriately high levels. In addition to its typical effect on ligand binding affinity, 
D97.103N eliminated functional activity at saturating agonist concentrations and at 
receptor expression levels at which wild-type-like functional activity was observed in 
D97N. Results from D69.97N indicated that the effects of D69N and D97N were 
approximately additive. Since the single mutant data was not available for D103, 
double mutant binding data from D69.103N and D97.103N were more difficult to 
interpret but the D103N mutation was not additive with D69N or D97N. Results from 
D97.103N suggest that D97 and D103 have separate noncooperative roles in ligand 
binding. D97N displayed reduced expression compared to wild-type and D103N was 
very poorly expressed in CHO cells, however D97.103N was expressed as well as 
D97N. Thermal inactivation studies suggested that these mutations had a small effect 
on receptor structure. 
Introduction 
Muscarinic acetylcholine receptors are members of a diverse group of receptors 
that are characterized structurally by a pattern of hydrophobic residues suggesting 
seven transmembrane domains, and functionally by coupling the binding of an 
extracellular activator to intracellular effector via G proteins. Five muscarinic receptor 
subtypes (ml m5) have been cloned and expressed (1-4). The odd-numbered subtypes 
couple preferentially to the stimulation of phospholipase C and the even-numbered 
subtypes couple preferentially to the inhibition of cAMP formation. The m2 subtype is 97 
widely distributed in mammalian tissue and is the only subtype found in mammalian 
heart (3), where in the cardiac pacemaker cells it inhibits adenylyl cyclase and 
stimulates inwardly-rectifying potassium channels and phospholipid metabolism via 
pertussis toxin-sensitive G proteins. Agonist binding to the cardic m2 muscarinic 
receptors slows the rate and decreases the force of contraction of the heart by at least 
two mechanisms. Voltage-gated calcium currents, regulated via cAMP levels, are 
reduced and inwardly-rectifying potassium currents are increased directly by the 
binding of Gh (5). 
The aspartate in transmembrane a-helix 2, residue D69 in the m2 muscarinic 
receptor, is conserved with some exceptions in the rhodopsin-like family of G protein-
coupled receptors. D103 in helix 3 is conserved in the class of receptors that bind the 
biogenic amines acetylcholine, dopamine, histamine, 5-hydroxytrypamine, 
norepinephrine, and octopamine and in the opioid and somatostatin peptide-binding 
receptors. D97 at the extracellular end of helix 3 is conserved less strictly among 
receptors that bind biogenic amines. It is conserved among the muscarinic receptors, 
most dopamine, and some 5-hydroxytrypamine and a-adrenergic receptors; glutamate 
is found at the homologous site in the P-adrenergic and some a-adrenergic receptors, 
while acidic residues are missing in the histamine and octopamine receptors. 
Double mutations involving the helix 2 aspartate have proved useful in other G 
protein-coupled receptors in identifying a spatial proximity between helix 2 and helix 7 
near the cytoplasmic face. A reciprocal double mutant between the conserved helix 2 
aspartate and a conserved asparagine in helix 7 of 5-hydroxytrypamine2A receptor 
(N436 in m2 muscarinic receptor) restored the high affinity agonist binding and 
functional activity lost in the single aspartate to asparagine mutation (6). Combined 
with similar reciprocal double mutant data from the gonadotropin-releasing hormone 
receptor (7), where these residues are switched in the native receptor and the mutant 98 
restored the typical arrangement of aspartate in helix 2 and asparagine in helix 7, led to 
the conclusion that these two residues are in close proximity and involved in a common 
hydrogen bond network (6). Helices 3 and 7 are in close proximity in rhodopsin where 
retinal is attached to a lysine in the middle of helix 7 via a protonated Schiff base the 
counterion for which is a glutamate at the intradiscal (extracellular homologous) end of 
helix 3 (8-10). Helices 3 and 6 are related to each other by the binding of agonist and 
perhaps functionally. A photoactivatable cross-linking analog of 11-cis-retinal 
predominantly labeled helices 3 and 6 (11); further studies led to a model of the light 
activation of rhodopsin that requires the relative rigid-body motion of helices 3 and 6 
(12, 13). A tyrosine residue near the extracellular end of helix 6 was identified in the 
m3 (14) and m2 (15) muscarinic receptors as being involved in differential agonist 
binding to the active and inactive receptor conformations and affecting functional 
activity as the result (15). Rhodopsin projection structures (16, 17) suggest a close 
proximity of helices 2 and 3, and two highly conserved motifs that could conceivably 
interact are found at the intracellular ends of these helices and are thought to be 
involved in the signal transduction (18). 
The conserved aspartates in helices 2 and 3 are suspected of having effects on 
functional activity (D69, helix 2) and agonist binding (D97 and D103, helix 3). To gain 
insight into how these effects might be related we examined the contribution these 
conserved aspartate residues make to the binding of receptor ligands and the roles they 
play in promoting the receptor state that is capable of activating G proteins both 
individually and in combination by examining both single and double mutants for each 
combination. To the best of our knowledge this is the first report of the examination of 
how these sites interact in any G protein-coupled receptor. 99 
Materials and Methods 
Materials 
[3H]QNB, [3H]NMS, [3H]oxotremorine M, and [14C]cAMP were purchased 
from DuPont NEN, [3H]adenine and [3H]myo-inositol from American Radio labeled 
Chemicals, acetylcholine and gallamine from Sigma, carbachol and pilocarpine from 
Aldrich, oxotremorine M and pirenzepine from Research Biochemicals, Gpp(NH)p 
from Boehringer Mannheim, Ro 20-1724 from Biomol, tissue culture media from 
Gibco/BRL, and the pcDNA3 expression vector from Invitrogen. The pSVE expression 
vector was kindly provided by Genentech and AF-DX 116 was a kind gift from 
Boehringer Mannheim. 
Tissue culture 
CHO cells deficient in dihydrofolate reductase activity (dhfr) (19) were 
transfected by the calcium phosphate method (20) with the pSVE expression vector (2) 
containing the coding region of the porcine m2 muscarinic acetylcholine receptor. The 
pSVE expression vector contains a mouse dihydrofolate reductase gene that permits the 
establishment of stable transfected cell lines under the selective pressure of 
methotrexate (0.5-5 p,M). Clonal cell lines were grown in Dulbecco's modified Eagle's 
media/Ham's F-12 (DMEM/F12) minus glycine, hypoxanthine, and thymidine, plus 
10% dialyzed calf serum and 10 tg/ml insulin. Cell lines were adapted to spinner 
culture as above except with 1 tg/ml insulin. For large scale preparations CHO cells 
were grown in DMEM/F12 plus 10% calf serum without selective pressure for 3-4 
days prior to harvesting to allow more rapid growth. The addition of sodium butyrate 
(5 mM) in the last 12-24 h prior to harvesting increased receptor expression 2-9-fold 
(21). CHO K1 cells, grown in DMEM/F12 plus 10% calf serum, were transfected by 
the lipofectase method with pcDNA3 expression vector containing D69.103N mutant 100 
muscarinic receptor gene. The transfected clonal CHO K1 cells were maintained under 
the selective pressure of 400 tg/m1 geneticin. 
Site-directed mutagenesis 
The aspartate mutant porcine m2 muscarinic receptors D69N, D97N, D103N, 
and D97.103N were produced by oligonucleotide-directed mutagenesis by the method 
of Kunkel et al. (22), while D69.97N and D69.103N were produced by the method of 
Vandeyar et al. (23). Double mutants were produced by sequential mutagenesis from 
single mutant templates. The wild-type coding region was ligated into M13mp18 as a 
HindlIllEcoRI fragment derived from the pSVE expression vector (2). The mutations 
were introduced by priming second strand synthesis with the antisense 
oligonucleotides: 5"-GATGAGGTTAGCACAGGC-3' (D69N), 
5'-CCAAAGGTTACACACCAC-3' (D97N), and 5'-CACGTAGTTCAGAGCTAG-3' 
(D103N) (base changes are underlined). Mutant sequences were confirmed by dideoxy 
sequencing (24). 
Ligand binding 
Ligand binding to enriched membrane preparations (25, 26) was assessed in 10 
mM HEPES, 5 mM MgC12, 1 mM EDTA, 1 mM EGTA, pH 7.4 at 25 °C. After 4-6 h 
samples were filtered through Schleicher & Schuell #32 glass-fiber filter membranes, 
pretreated with 0.1% (w/v) polyethylenimine, on a Brandel Harvester (Gaithersburg, 
Maryland) and washed with approximately 10 ml ice-cold 50 mM sodium phosphate, 
1 mM EDTA, pH 7.4. Filter binding assays on D103N-containing mutants were done 
on samples that were chilled on ice briefly prior to 6 ml wash with ice-cold buffer. 
Nonspecific binding was assessed in the presence of excess unlabeled ligand. NMS and 
QNB binding results are from direct binding of the radiolabeled ligand except for the 
D97.103N mutant, where NMS affinity was determined in competition with [3H]QNB. 101 
Other ligand affinities were determined in competition with either [3H]NMS or 
[3H]QNB or both. 
Protein stability 
Resistance to thermal inactivation was assessed in enriched membrane 
preparations in the presence and absence of saturating [3H]QNB (10-fold or greater 
K &. Membranes were exposed to different temperatures for 1 h, quenched on ice, and 
residual [3H]QNB binding determined. 
Effector Coupling 
Phosphatidylinositol stimulation was determined in attached CHO cells 
expressing mutant muscarinic receptor plated at 2 x 104/mm2 and incubated in 4 
[3H]myo- inositol for 72 h. Agonists were added and inositol 1-phosphate 
accumulation was measured after 30 min at 37 °C as described by Lee et al. (27). 
Inhibition of forskolin-stimulated adenylyl cyclase activity was determined in attached 
confluent CHO cells in the presence of 100 [tM isobutylmethylxanthine, 50 [IM Ro 20­
1724, and agonist after exposing the cells to 8 pCi/m1 [3H]adenine for 2-3 h. The 20 
min assay at 37 °C was started by the addition of 40 [tM forskolin and [3H]cAMP was 
determined according to the method of Salomon (28). In order to have comparable 
receptor densities, wild-type receptor levels were reduced in some experiments by 
incubating the cells 1 h at 37 °C with varying concentrations of the slowly dissociating 
antagonist QNB (29). 
Data Analysis 
Functional assays were fit to Equation 1, where [x] is the agonist concentration, 
max1,2 are the maxima of the inhibitory and stimulatory portions of the curve, min is 
the minimum of the curve, and p1,2 are the respective slope factors. For adenylyl 
cyclase assays that showed only an inhibitory phase the first two terms were used and 102 
for assays of phosphatidylinositol metabolism stimulation the first and last terms were 
used. 
max  min  max2  min
CPM =min + 
x []  (EC50S)2 
1 + 
(EC50i)  [x]  )  (1) 
In direct saturation binding experiments total bound radioligand was analyzed as the 
sum of specific, [RL], and nonspecifically, N[L], bound ligand according to the 
quadratic solution of Equation 2 and Equation 3, where [Ro] and [Lo] are the total 
receptor and ligand concentrations, K is the equilibrium dissociation constant, and N is 
the proportionality constant of nonspecifically bound ligand to free ligand 
concentration. 
[Rn)
[Rn=([1?°][Rn)([1,0]  (2)
K(N +1) 
[R1-]) N[n= N`[L0  (3)
N + 1 
Agonist and unlabeled antagonist binding was assessed in competition with 
radiolabeled antagonist. Agonist binding data were fit to one to three noninteracting 
classes of sites that bound antagonist with the same dissociation constant. Total labeled 
antagonist specifically bound, [RI], is the sum of that bound at each subclass of agonist 
binding sites according to the polynomial solutions to Equation 4,2 
[RL]  n  F i[RolL01[Rn) 
K(N + 1)(1+ fp)+[4 ]_[Rn 
(4) 
2Expanded solutions of these equations appear in the Appendix to this dissertation. 103 
where [Rd equals the total concentration of receptor, Fi is fraction of [Ro] at site i, 
[Lo] is the total labeled antagonist concentration, [A] is the total agonist concentration 
(equal to the free concentration since no displacement occurs until [A] > [Rd), K is the 
dissociation constant for radiolabeled antagonist, and Ki is the dissociation constant for 
the agonist at site i (referred to as Kw Km, and KL, the high, medium, and low affinity 
constants).2 Data were fit by nonlinear least-squares procedures using Marquardt's 
algorithm (30) and parameter values are reported as the mean and 95% confidence 
interval of several determinations. 
Ligand binding energetics 
The difference in standard free energies for ligand binding between mutant and 
wild-type muscarinic receptors was calculated with Equation 5, 
= AG°Mutant AG °Wild-type = RT ln(KmutantiKwi Id-type) 
(5) 
where AG° is the standard Gibbs free-energy change, R is the gas constant, T is the 
absolute temperature, and K is the equilibrium dissociation constant. A(AG°) is the 
apparent difference in binding energy contribution between the carboxylate anion of 
aspartate and the neutral asparagine amide (31); it does not take into account the 
changes in solvation of the mutant receptor or potential changes in receptor stability. 
A(AG°) is defined such that positive values indicate that the mutant binds ligand more 
weakly than wild-type. 
Results 
Mutagenesis and expression 
Three aspartate residues located in the putative transmembrane region of the m2 
muscarinic receptor were mutated individually and in pairs to asparagine and stably 
expressed in cloned CHO cells. Experiments on D103N and D69.103N expressing cell 104 
lines were hampered by poor expression of antagonist binding sites. Similar problems 
precluded the characterization of the D103N homologous mutation in the ml 
muscarinic receptor (32). The limited data obtained on the D69.103N mutant was 
obtained from CHO cells transfected with an alternative expression vector (pcDNA3) 
and although clonal cell lines were isolated, expression of antagonist binding sites were 
not stable. Fortunately, the D97.103N mutant was stably expressed at high enough 
levels; since the D97N mutant was nearly fully functional (below) it was possible to 
characterize the effect of mutating residue 103 to asparagine. Except for an estimation 
of QNB affinity the D103N mutation was not characterized directly; an alternate 
expression vector was not pursued. 
Binding studies 
Ligand binding properties were assessed in sucrose gradient-enriched 
membrane preparations from spinner culture-adapted CHO cells. Characterization of 
the D103N-containing mutants was complicated by the high dissociation rate of 
radiolabeled antagonists QNB and NMS and the requirement for high-level expression 
due to the resulting low antagonist affinity of these mutants. The rate constant for QNB 
dissociation from D97.103N mutant at 0 °C was approximately 5 x 10-3 s-1 and 5-fold 
faster for NMS (data not shown). Because of this rate D103N-containing mutants were 
characterized with QNB via a slightly altered filter procedure (see Materials and 
Methods). In control experiments QNB affinity constants were determined by an 
alternate procedure that used an air-driven ultracentrifuge to separate bound from free 
ligand and results were indistinguishable from those obtained by the modified filter 
assay. 
The results of ligand binding studies are presented in Table 4.1. Antagonists 
AF-DX 116, hyoscyamine, NMS, pirenzepine, and QNB bound to a single class of 
sites in both the wild-type and mutant receptors. Gallamine binds to a competitive site 105 
and an allosteric site, which has the effect of reducing the dissociation rate of other 
ligands (33), but only the affinity for the competitive site was determined. Agonists 
appeared to bind to three classes of sites in membrane preparations containing wild-
type m2 muscarinic receptor. The highest affinity site, KH, was sensitive to guanine 
nucleotide consistent with binding to the receptorG protein complex; the lower 
affinity site, KM, appeared to be the free receptor since its relative proportion increased 
in the presence of guanine nucleotides. The concentration of the lowest affinity site, KL, 
was not affected by guanine nucleotides and its role has not been assigned (29). 
Agonist competition binding assays were conducted in the presence and absence of 
Gpp(NH)p, a nonhydrolyzable analog of GTP. Data obtained in the presence and 
absence of guanine nucleotides were fit so that values for KH, KM, and KL were shared 
in the analysis of a given experiment. Examples of some of these experiments appear in 
Figure 4.1. Mutations incorporating D69N and/or D103N did not display high affinity 
guanine nucleotide-sensitive agonist binding in competition binding experiments; this 
site was evident only in wild-type and the D97N mutant. Additionally, no high affinity 
guanine nucleotide-sensitive [3H]oxotremorine M was detectable in the D69N mutant-
expressing membrane preparations (data not shown). 
Values for A(AG°) between the asparagine mutant and the wild-type aspartate 
derived from the data in Table 4.1 are presented in Table 4.2 as are the double mutant 
cycle results for D69N , D97N, and D69.97N. The A(AG°)s for the D103N mutant 
were calculated as the difference between the D69.103N and D69N and between 
D97.103N and D97N: the A(AG°)s values calculated using D69.103N and D69N were 
significantly greater than the values calculated using D97.103N and D97N. 90T 
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Table 4.1, continued 
D69.97N  D69.103N  D97.103N 
Antagonists 
NMS 
QNB 
AF-DX 116 
pirenzepine 
hyoscyamine 
gallamine 
AgonistsKH 
pM 
pM 
nM 
nM 
nM 
nM 
675 ± 108 (5) 
116 ± 51(7) 
227 ± 191(3) 
1280 ± 110 (3) 
5.7 ± 4.6 (3) 
110 ± 61(2) 
32,500 ± 5200 (3) 
32,600 ± 7200 (9) 
12,200 ± 2080 (13) 
17,000 ± 7000 (5) 
9000 ± 1600 (5) 
110 ± 37 (5) 
12,200 ± 2080 (13) 
acetylcholine 
carbachol 
nM 
nM 
oxotremorine M  nM 
pilocarpine  nM 
AgonistsKm 
acetylcholine 
carbachol 
oxotremorine M 
pilocarpine 
AgonistsKL 
.tM 
11M 
1AM 
.tM 
1.9 ± 1.4 (4) 
8.1 ± 3.1 (7) 
3.2 ± 3.1 (4) 
5.0 ± 3.1 (3) 
22,700 ± 16,000 (3) 
30,000 ± 120,000 (2) 
16,700 ± 15,700 (2) 
740 ± 4300 (2) 
21,700 ± 10,500 (5) 
8800 ± 2000 (16) 
1250 ± 350 (11) 
1040 ± 130 (7) 
acetylcholine 
carbachol 
oxotremorine M 
pilocarpine 
i.tM 
1.tM 
[tM 
.tM 
35 ± 10 (4) 
110 ± 27 (8) 
270 ± 160 (4) 
120 ± 170 (3) 
183,000 ± 73,000 (8) 
133,000 ± 2.6x10
6 (2) 
34,000 ± 21,000 (4) 108 
Figure 4.1. Agonist displacement by oxotremorine M of wild-type and asparagine 
mutant muscarinic receptors in CHO cell membranes. Data were fit to independent 
classes of sites, described in Materials and Methods. The parameter values for the fitted 
lines are shown ± asymptotic standard errors. Wild-type KH= 3.0 ± 0.7 nM, Km= 0.18 
± 0.02 gM, KL = 7.5 ± 1.0 pm, total [3H]NMS = 2.1 nM, total receptor = 100 pM, Fri = 
51.6 ± 2.2%, FM = 30.7 ± 2.8%, in the absence of Gpp(NH)p ( ), and FH = 0% 
(fixed), FM = 84.2 ± 1.6%, in the presence of 100 µM Gpp(NH)p (0 ). D69N KM = 8.1 
± 0.9 gM, KL = 166 ± 10 pM, total [3H]NMS = 4.1 nM, total receptor = 500 pM, FM = 
55.7 ± 2.2%, in the absence of Gpp(NH)p ( ), and FM = 54.1 ± 2.3%, in the presence 
of 100 pm Gpp(NH)p (0 ). D97N KH = 12.9 ± 3.1 nM, KM = 4.8 ± 0.3 gm, KL = 488 ± 
9 pM, total [3H]NMS = 1.7 nM, total receptor = 390 pM, FH = 37.9± 1.6%, FM = 57.7 ± 
1.6%, in the absence of Gpp(NH)p (0 ), and FH = 19.4 ± 2.2%, FM = 76.1± 2.1%, in 
the presence of 100 pM Gpp(NH)p (0 ). D97.103N KM = 1000 ± 80 gm, total 
[3H]NMS = 35.7 nM, total receptor = 6.5 nM, in the absence of (9 ) and presence of 
100 gM Gpp(NH)p (0 ). Fraction of total receptor specifically bound is plotted. 109 
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Table 4.2. A(AG°) for m2 muscarinic receptor aspartate mutants. A(AG°) =
 
AG° (mutant) AG° (wild-type). A(AG°) values were calculated from data in Table 4.1
 
and are presented kcal/mol ± 95% confidence interval; ns, indicates value not
 
significantly different from zero.
 
D69N 
Antagonists 
NMS  ns 
QNB  ns 
AF-DX 116  ns 
pirenzepine  0.53 ± 0.41 
hyoscyamine  ns 
gallamine  1.21 ± 0.28 
Agonists-KHa 
acetylcholine 
carbachol 
oxotremorine M 
pilocarpine 
Agonists-Kma 
acetylcholine  0.38 ± 0.21 
carbachol  0.55 ± 0.22 
oxotremorine M  1.28 ± 0.61 
pilocarpine  ns 
Agonists-ka 
acetylcholine  ns 
carbachol  ns 
oxotremorine M  ns 
pilocarpine  ns 
D97N 
ns 
1.01 ± 0.12 
0.69 ± 0.27 
0.55 ± 0.37 
ns 
ns 
1.86 ± 0.60 
0.83 ± 0.32 
1.08 ± 0.32 
1.35 ± 0.38 
1.84 ± 0.43 
0.54 ± 0.59 
1.50 ± 0.21 
0.38 ± 0.20 
1.39 ± 0.52 
0.91 ± 0.30 
1.98 ± 0.75 
1.56 ± 0.43 
D103N 
4.44 ± 5.15 
D69.97N  D69.103N 
0.58 ± 0.13 
1.12 ± 0.26  4.46 ± 0.11 
ns 
0.89 ± 0.37 
0.82 ± 0.48 
0.48 ± 0.27 
0.99 ± 0.43  6.57 ± 0.12 
1.05 ± 0.24  5.92 ± 2.47 
1.23 ± 0.45  6.31 ± 0.23 
0.34 ± 0.29  3.31 ± 3.57 
0.68 ± 0.24 
0.96 ± 0.17 
1.80 ± 0.43 
0.95 ± 0.64 
a Indicates the equilibrium constant for which the A(AG°) values were calculated. A(iG°) for D103N 
mutation calculated from the difference between the double and single mutants. 112 
Table 4.2, continued 
D69.103N  D97.103N  D69.103N  D97.103N  D69.97N 
D69Nb  D97Nb  (D69N + D97N) 
Antagonists 
NMS  2.88 ± 0.16  2.84 ± 0.06  0.445 ± 0.076 
QNB  4.46 ± 0.11  3.88 ± 0.13  4.42 + 0.08  2.87 ± 0.06  ns 
AF-DX 116  2.60 ± 0.32  1.91 ± 0.16  -0.73 ± 0.19 
pirenzepine  2.05 ± 0.38  1.50 ± 0.21  0.83 ± 0.25 
hyoscyamine  2.57 ± 0.35  2.34 ± 0.15  ns 
gallamine  2.10 ± 0.23  2.10 ± 0.06  -0.64 ± 0.22 
Agonists-KHa 
acetylcholine 
carbachol 
oxotremorine M 
pilocarpine 
Agonists-Kma 
acetylcholine  6.57 ± 0.12  6.54 ± 0.29  6.19 ± 0.23  4.70 ± 0.34  -1.23 ± 0.39 
carbachol  5.92 ± 2.47  5.19 ± 0.15  5.4 ± 2.6  4.66 ± 0.54  ns 
oxotremorine M  6.31 ± 0.23  4.77 ± 0.25  5.03 ± 0.50  3.27 ± 0.07  -1.56 ± 0.47 
pilocarpine  3.31 ± 3.57  3.51 ± 0.17  ns  3.13 ± 0.09  ns 
Agonists-KLa 
acetylcholine  -0.81 ± 0.25 
carbachol  5.36 ± 0.25  4.44 ± 0.24  ns 
oxotremorine M  ns  3.49 ± 0.48  -0.44 ± 0.35 
pilocarpine  4.27 ± 0.45  2.71 ± 0.20  -0.94 ± 0.40 
aIndicates the eauilibrium constant for which the MAG°1 values were calculated bA(AG°1 for Dl OW 
mutation calculated from the difference between the double and single mutants. 113 
Thermal inactivation 
Resistance to irreversible thermal inactivation in the presence and absence of 
the antagonist QNB was used to assess the effects of the mutations on m2 muscarinic 
receptor structure (Table 4.3). The QNB-bound receptor state was clearly more stable 
to thermal inactivation than the unliganded state in the wild-type receptor. The D69N 
mutant was indistinguishable from wild-type receptor in its resistance to thermal 
inactivation of ligand binding. The loss of this aspartate charge did not significantly 
destabilize receptor structure. In the absence of QNB the differences between all 
mutants were either small or not significant. The effect of mutations was mainly seen 
in the receptor state that was stabilized in wild-type by QNB binding. In mutants 
missing the anionic charge at residue 103 (D69.103N and D97.103N) the stabilizing 
effect of QNB binding on thermal inactivation was eliminated. For mutants missing the 
aspartate charge at residue 97 (D97N and D69.97N) the results are less dramatic but the 
amount of stabilization to thermal inactivation by QNB was reduced. 
Table 4.3. Irreversible thermal inactivation of mutant and wild-type m2 
muscarinic receptor in presence and absence of saturating QNB. Mean T05 (°C) 
are presented ± 95% confidence interval and the number of experiments are indicated 
in parentheses. 
-QNB  +QNB  Apairwisea 
Wild-type  54.1 ± 1.6 (15)  60.2 ± 1.3 (16)  6.2 ± 0.9 (15) 
D69N  56.1 ± 1.9 (3)  62.1 ± 0.8 (3)  6.1 ± 2.9 (3) 
D97N  53.8 ± 1.5 (3)  57.6 ± 2.7 (3)  3.8 ± 1.0 (3) 
D69.97N  51.0 ± 4.8 (4)  55.4 ± 4.1 (4)  4.6 ± 2.5 (4) 
D69.103N  52.9 ± 1.4 (3)  53.1 ± 0.7 (3)  ns (3) 
D97.103N  50.4 ± 4.9 (3)  50.3 ± 4.3 (3)  ns (2) 
aThe stabilizing effect of QNB calculated as the paired difference for experiments that simultaneously 
determined the Ta5 in the presence and absence of QNB; ns indicates that QNB did not significantly 
affect stability. 114 
Functional activity 
Functional coupling of the mutant receptor was analyzed in attached tissue culture cells 
and the results compared to wild-type receptor at similar expression levels. Results 
with the wild-type expressing cell line varied with receptor density. To provide a valid 
basis of comparison the receptor density of the wild-type expressing cell line was 
reduced with the slowly dissociating antagonist QNB (29). The m2 muscarinic 
receptor-expressing cell line stimulated phosphatidylinositol metabolism to a maximal 
extent that varied proportionally with receptor density while the concentration of 
agonist that produced a half-maximal response (EC50) was independent of receptor 
density (Table 4.4). In contrast, the EC50 for the inhibition of adenylyl cyclase was 
inversely proportional to receptor density while the maximal response did not vary 
significantly with acetylcholine, carbachol, and oxotremorine M. Maximal response 
with pilocarpine was less than the other agonists at low receptor density, displaying 
partial agonism, and equal in extent to the other agonists at high receptor density 
(Table 4.5). In addition, the effect on cAMP levels was biphasic, inhibitory at low 
agonist concentration and stimulatory at high agonist concentrations. The pertussis 
toxin-insensitive stimulatory phase was only observed at relatively high expression 
levels and increased proportionally with receptor level; the EC50 for stimulation of 
adenylyl cyclase was inversely proportional to receptor density. 
The D97N mutant was the most wild-type-like of the asparagine mutant 
receptors. The D97N mutant inhibited cAMP formation to an extent indistinguishable 
from wild-type and stimulated phosphatidylinositol metabolism to an extent slightly 
less than wild-type at comparable receptor densities. The stimulation of cAMP 
formation observed in wild-type was also observed in the D97N mutant but only at the 
highest receptor density examined. The highest receptor density available in cells 
expressing the D97N mutant was approximately half the density required in the 115 
Table 4.4. Effect of aspartate mutant muscarinic receptor on phosphatidylinositol 
stimulation. Values for ECK, and fold maximal stimulation of phosphatidylinositol 
metabolism are shown for the indicated receptor site densities; n, indicates the number 
of experimental determinations; ns, indicates that no significant stimulation was 
observed. 116 
n  EC50 a  Fold Stimulation"  [R] 
(,11\11)  (pmol.dm-2) 
acetylcholine  19  0.13 ± 0.11  1.2-2.3  0.3-32 
carbachol  27  1.4 ± 0.8  1.2-2.7  1.6-42 
oxotremorine M  34  0.45 ± 0.64  1.2-2.4  1.2-42 
pilocarpine  12  14 ± 12  1-1.8  1.6-32 
D69N 
acetylcholine  5  ns  15-120 
carbachol  5  ns  65-120 
oxotremorine M  5  1.0 ± 1.4  1.41 ± 0.13  65-120 
pilocarpine  2  ns  65-69 
D97N 
acetylcholine  4  23 ± 28  2.13 ± 0.29  7-10 
carbachol  6  10.2 ± 2.0  1.73 ± 0.24  7-38 
oxotremorine M  4  4.2 ± 2.2  1.79 ± 0.23  7-10 
pilocarpine  2"  31 ± 17  1.47 ± 0.09  10 
D69.97N 
acetylcholine  3  ns  10-27 
carbachol  7  ns  10-27 
oxotremorine M  7  17 ± 14  1.42 ± 0.12  6-25 
pilocarpine  2  ns  14 
D97.103N 
acetylcholine  5  ns  3.8-15.9 
carbachol  4  us  3.8-15.9 
oxotremorine M  5  ns  3.8-15.9 
pilocarpine  4  ns  3.8-15.9 
aEC50 and fold maximal stimulation values are presented ± standard deviation or for wild-type fold 
maximal stimulation as a range that increased with [R]. bWild-type data include experiments where the 
cell surface receptor density was reduced by incubating the cells with QNB to provide a wide range of 
receptor densities for comparison with mutants. cln two additional experiments pilocarpine failed to 
stimulate phosphatidylinositol metabolism significantly ([R] = 7-9 pmol.dm-2). 117 
Table 4.5. Effect of aspartate mutant muscarinic receptor on adenylyl cyclase 
activity. Values for EC50, percent inhibition, and fold stimulation of adenylyl cyclase 
are shown for the indicated receptor site densities; n, indicates the number of 
experimental determinations; ns, indicates that no significant effect was observed. 
n  EC50i (PO  Inhibition 
(%)b 
EC50s (1.1M)d  Fold 
stimulationb 
[R] 
(pmoldm-2) 
wild -types 
acetylcholine  7  0.005-0.093  78.3 ± 9.6  1.3-33,000  0-1.6  4-50 
carbachol  18  0.0002-39  63.2 ± 8.1  4.8-180  0-2.6  1-60 
oxotremorine M  11  0.003-0.45  76.0 ± 4.4  1.6-10,000  0-1.2  4-73 
pilocarpine  17  0.8-60  30-79  ns  3-52 
D69N 
acetylcholine  6  ns  0.56 ± 0.53d  1.29 ± 0.12  20-200 
carbachol  4  ns  1.15 ± 0.72d  1.35 ± 0.14  20-200 
oxotremorine M  10  10.2 ± 8.6d  40.6 ± 4.7  ns  20-200 
pilocarpine  2  ns  ns  84 
D97N 
acetylcholine  2  0.13-0.39e  75.9 ± 3.5  10f  0.5f  15-26 
carbachol  5  0.49-10e  75.6 ± 6.1  730f  0.7f  4.7-26 
oxotremorine M  4  0.1-3e  80.3 ± 2.7  36f  0.61  4.7-26 
pilocarpine  5  19-200e  28-74  ns  4.7-26 
dEC50 values for the inhibitory (EC50i) and the stimulatory phase (EC50s) that are reported as a range 
varied inversely with [R] while values that are reported ± standard deviation appeared to be constant 
over the indicated range of [R]. bInhibition and stimulation values that are reported as a range varied 
proportionally with [R] while values that are reported ± standard deviation appeared to be constant over 
the indicated range of [R]. cWild-type data include experiments where the cell surface receptor density 
was reduced by incubating the cells with QNB to provide a wide range of receptor densities for 
comparison with mutants. dThe observed wild-type oxotremorine M EC50i for this receptor site density 
is 7-9 nM; the observed wild-type EC50s is 1-10 [IM for acetylcholine and 4-20 aM for carbachol. efhe 
observed wild-type EC50i for [R] = 26 pmol dm-2 is 9.6 nM, 40 nM, 8.5 nM, and 3 pM for 
acetylcholine, carbachol, oxotremorine M, and pilocarpine, respectively. (Data are the results of a single 
experiment at 26 pmol dm-2; in addition oxotremorine M stimulates at 15 pmol dm-2 (150 KM, 0.3 fold) 
while acetylcholine and carbachol did not. 118 
Table 4.5, continued 
EC50i (1-1Mr  Inhibition  EC50s (113,4)a  Fold  [R] 
(%)b  stimulationb  (pmoldm-2) 
D69.97N
 
acetylcholine  7  ns  ns  4-27 
carbachol  9  ns  ns  4-27 
oxotremorine M  8  167  ± 1008  41 ± 16  ns  4-27 
pilocarpine  2  ns  ns  12 
D97.103N
 
acetylcholine  3  ns  ns  2-33 
carbachol  3  ns  ns  2-33 
oxotremorine M  5  ns  ns  2-33 
pilocarpine  2  ns  ns  2-23 
aEC50 values for the inhibitory (EC50i) and the stimulatory phase (EC50s) that are reported as a range 
varied inversely with [R] while values that are reported ± standard deviation appeared to be constant 
over the indicated range of [R]. bInhibition and stimulation values that are reported as a range varied 
proportionally with [R] while values that are reported ± standard deviation appeared to be constant over 
the indicated range of [R]. gThe observed wild-type EC50i for [R] =27 pmol dm-2 is 8.5 nM. 119 
Figure 4.2. Stimulation of phosphatidylinositol metabolism by aspartate mutant 
muscarinic receptors. Illustrated experiments were conducted on whole attached CHO 
cells expressing mutant receptor at the following levels (pmol dm-2): D69N, 120 (0 , 
), 69 (A , V ); D97N, 10; D69.97N, 14; and D97.103N, 10 (0,  ), 16 (A ,  V ). The 
lines represent logistic fits of the data where significant stimulation was observed, as 
described in Materials and Methods. Symbols: acetylcholine (0), carbachol ( ), 
oxotremorine M (A ), pilocarpine (V ), filled symbols indicate response in the presence 
of the antagonist hyoscyamine. 
Figure 4.3. Effect of aspartate mutant muscarinic receptors on cAMP formation. 
Illustrated experiments were conducted on whole attached CHO cells expressing 
mutant receptor at the following levels (pmol dm-2): D69N, 200 (0 , 0, A), 84 (V ); 
D97N, 26; D69.97N, 20 (0 ), 17 (0, A ,  V) and D97.103N, 33 (0 ,  , A ), 23 (V ). 
The lines represent logistic fits of the data where significant stimulation was observed, 
as described in Material and Methods. Fitted parameters are summarized in Table 4.5. 
Symbols: acetylcholine (0), carbachol ( ), oxotremorine M (A ), pilocarpine (V ), 
filled symbols indicate response in the presence of the antagonist hyoscyamine. 120 
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wild-type-expressing cell line needed to accurately quantitate this effect, making a 
comparison unreliable. The changes in EC50s for agonist stimulation of phosphatidyl­
inositol metabolism and inhibition of cAMP formation are consistent with the 
decreased agonist affinity (Table 4.1). 
The D69N and D69.97N mutant-expressing cell lines did not stimulate 
phosphatidylinositol metabolism or inhibit adenylyl cyclase activity with the agonists 
acetylcholine, carbachol, or pilocarpine. In contrast, oxotremorine M partially activated 
both effector systems (Figures 4.2 and 4.3, Tables 4.4 and 4.5). The changes in EC50 
for both effects are consistent with the decreased agonist affinity (Table 4.1). 
Acetylcholine and carbachol stimulated adenylyl cyclase activity in the D69N 
expressing cell line to an extent that was less than the similar stimulation observed in 
the wild-type expressing cell line with an EC50 that was similar to that observed in 
wild-type. As was found for this effect in wild-type (29), pertussis toxin did not 
eliminate it suggesting that it was not a Gi or Go dependent process. The EC50 
observed in D69N for the stimulation of adenylyl cyclase was not significantly 
different from wild-type but the maximal effect was less than found in wild-type at 
comparable receptor density. 
The D97.103N mutant was alone among the three D103N-containing mutants 
in that, as measured by antagonist binding, it was expressed at high enough levels to 
allow valid comparisons of its ability to activate effector systems. The D97.103N 
mutant at saturating agonist concentrations did not appear to stimulate 
phosphatidylinositol metabolism or inhibit adenylyl cyclase activity at receptor 
densities where these responses are observable for the D97N mutant. 
Discussion 
In seeking to understand the relationship between agonist binding and receptor 
activation double mutants of the conserved aspartate in the second transmembrane 125 
helix and the conserved aspartates in the third transmembrane helixwere examined. 
Potential interactions between the two helix 3 aspartates were also examined. The 
conserved aspartate residue in helix 2 (D69 in the m2 muscarinic receptor) is known to 
be involved mainly in signal transduction. The conserved aspartate residue in helix 3 
(D103 in the m2 muscarinic receptor) plays a significant role in the binding of ligands 
in the amine-binding receptors, while the aspartate at the extracellular end of helix 3 
(D97 in the m2 muscarinic receptor), conserved in the muscarinic receptors and less 
strictly among other amine-binding receptors, plays a less significant role in ligand 
binding. Neither of these two helix 3 residues was thought to play a significant role in 
the receptor signal transduction that could not be ascribed to reduced agonist affinity. 
We found this to be true for D97 but not true for D103. 
The role of D103 
Among G protein-coupled receptors that bind biogenic amines the carboxylate 
residue in the third transmembrane helix (D103 in the m2 muscarinic receptor) has 
been shown to be critical for binding of agonists and antagonists (34-41). In the x2­
(36) and 02-adrenergic (35), 5-hydroxytrypaminem (41), and 5-hydroxytrypamine2 
(37) receptors the effect of mutating this site to asparagine appears limited to ligand 
affinity. The functional activity of these receptors was preserved and their EC50s were 
affected consistent with their dramatically decreased agonist affinity. In muscarinic 
receptors this site is critical for both agonist binding and functional activity. The 
homologous mutation in the ml muscarinic receptor eliminated acetylcholine-
promoted phosphatidylinositol stimulation while the glutamate mutation preserved 
partial activity (39). Results with the D97.103N double mutant when compared with 
the D97N mutant indicate that the incorporation of asparagine at residue 103 
eliminated both high affinity agonist binding and receptor functional activity. 126 
The dramatic decrease in ligand affinity that occurs when this negatively 
charged group is substituted by an uncharged polar group (Tables 4.1 and 4.2) suggests 
that D103 is the ligand amine counterion. This conclusion is supported by experiments 
in the ml muscarinic receptor where agonist (42) and antagonist (43, 44) affinity 
alkylating agents modified and sequencing experiments identified the homologous 
aspartate as being in the binding pocket. However, this conclusion must be considered 
tentative in the absence of high resolution structures of the receptor and receptor 
ligand complexes and an alternative mechanism for the binding of amine ligands. 
Aromatic cation-ic binding of acetylcholine was observed in the high resolution 
structure of acetylcholinesterase (45), implicated in the binding of acetylcholine to the 
nicotinic acetylcholine receptor (46, 47), and proposed for m2 muscarinic receptor in 
combination with an anionic site (48). In the acetylcholinesterase crystal structure a 
conserved glutamate residue is positioned at the bottom of a solvent-accessible pit lined 
with aromatic residues. The structure indicated that the quaternary ammonium ion on 
acetylcholine interacted with the TC ring current on the aromatic residues not the 
conserved glutamate (45). Subsequent site-directed mutagenesis experiments on this 
glutamate provided support to the conclusion that it is not part of the acetylcholine 
binding site (49, 50). The muscarinic receptor also has a large number of aromatic 
residues in and near the transmembrane a-helices that could conceivably form a similar 
aromatic lined pit with aspartate at the bottom, but unlike the mutagenesis results on 
acetylcholinesterase, eliminating the charge dramatically affects binding in muscarinic 
receptors. Aromatic residues do play a role in the binding of amine ligands as indicated 
by site-directed mutagenesis studies on transmembrane aromatic residues in the m3 
(14, 51) and m2 muscarinic receptors (15), but evidence to date indicates that role to be 
secondary to the role of the anionic site D103. 127 
The lack of a functional response in the cell line expressing the D97.103N 
mutant and the lack of guanine nucleotide-sensitive agonist binding suggest two 
possible explanations of the role of D103 with respect to receptor activity. First, the 
active receptor conformation exists in equilibrium with the inactive conformation but 
agonist cannot differentially stabilize it, D103 being significantly more important to the 
active agonist-bound receptor conformation that interacts with G protein than to the 
inactive agonist-bound conformation. At the extreme where agonist binds to both 
conformations with equal affinity, agonist binding would have no effect on the 
distribution of active and inactive receptor conformational states. Although the total 
concentration of active receptor would be unaffected, the formation of agonist 
receptorG protein ternary complex from receptorG protein binary complex could 
result in functional activity in the absence of measurable guanine nucleotide-sensitive 
agonist binding. A second possibility is that the active conformation of the receptor is 
dependent on the presence of an anionic residue at position 103. In its absence the 
conformational transition to the active state does not occur so that only the inactive 
conformation exists in the mutant receptor. In light of the results from the D69N­
containing mutants, where partial activity was preserved in the absence of high affinity 
guanine nucleotide-sensitive agonist binding, the second possibility appears to be the 
best explanation. 
Poor expression of antagonist binding sites prevented direct characterization of 
the D103N mutation in CHO cells. When the D103 homologous residue was mutated 
to asparagine in the ml muscarinic receptor mRNA blots from stably transfected CHO 
cells indicated that gene transcription was unaffected; specific [3H]QNB binding 
however was undetectable (32). Agonist affinities for this cell line were later 
determined by competition binding when specific [3H]NMS binding was detected (39). 
Mutant proteins containing glutamate at this site were better expressed (38, 39) while 128 
expression of an alanine mutant was undetectable (38). These results and those reported 
here lead to the conclusion that the absence of a carboxylate-bearing functional group 
at this location introduced a barrier to proper protein folding or processing in 
muscarinic receptors but leaves unexplained the compensating effect of the mutation at 
residue 97 observed in the double mutant D97.103N. The involvement of this 
conserved residue in protein folding or processing is not a general characteristic of this 
class of receptors, as homologous mutations in 02-adrenergic (34), a2A-adrenergic 
(36), 5-hydroxytrypamine2 (37), and histamine H1 (40) receptors, other G protein-
coupled receptors that bind biogenic amines, appeared to be well tolerated. Asparagine 
mutations at this homologous site in the histamine H2 (52) and the dopamine D2 (53) 
receptors also resulted in undetectable cell surface expression; however, it is unclear if 
this was due to poor protein expression or dramatically decreased ligand affinity. 
The role of D69 
The D69N and D69.97N mutant-expressing cell lines display agonist-specific 
functional activity and agonist-specific changes in the specificity of functional activity. 
D69N and D69.97N failed to stimulate phospholipase C or inhibit adenylyl cyclase via 
acetylcholine, carbachol, or pilocarpine but were capable of eliciting a functional 
response with oxotremorine M. High affinity guanine nucleotide-sensitive agonist 
binding was not observed in competition experiments with any agonist or in the more 
sensitive direct binding of [3H]oxotremorine M. Except for the lack of detectable 
guanine nucleotide-sensitive high affinity agonist binding, D69 does not contribute 
significant energy to the binding of ligands with the exception of the antagonist 
gallamine and the agonist oxotremorine M (Table 4.2). 
The explanation that is most consistent with the data is that an acidic residue at 
position 69 is critical to the binding of agonist to the high affinity guanine nucleotide-
sensitive agonist binding site. Microscopically, D69 might contribute binding energy to 129 
the stabilization of agonist in the binding pocket when the receptor is in its active 
conformation and bound to G protein or by stabilizing the active receptorG protein 
complex. Since this aspartate is conserved across the rhodopsin-like family of G 
protein-coupled receptors, the possibility that D69 stabilizes the active conformation of 
the receptor is the more likely explanation. 
Until now there has been little reason to suspect there was more than a single 
active receptor conformation. Phospholipase C stimulation and the biphasic inhibition 
and stimulation of adenylyl cyclase could be adequately explained by different G 
proteins interacting with a single active receptor conformation. Different agonist-bound 
states, although formally distinct, appeared to activate G proteins in a manner that was 
approximately dependent on the binding characteristics of the specific agonist. This 
was not so with the D69N and D69.97N mutants. The receptor conformation that 
results in high affinity guanine nucleotide-sensitive agonist binding was either lost or 
its affinity was dramatically altered in the D69N-containing mutants; the simplest 
explanation is that any effects originating from this state would be lost or similarly 
altered. This adequately explains the loss of adenylyl cyclase inhibition and 
phospholipase C stimulation promoted by acetylcholine, carbachol, and pilocarpine and 
the loss of adenylyl cyclase stimulation promoted by oxotremorine M. The observed 
oxotremorine M-promoted adenylyl cyclase inhibition and phospholipase C stimulation 
and the adenylyl cyclase stimulation promoted by acetylcholine and carbachol suggest 
alternative or additional agonist-specific routes to these effects were available. The 
results with the D69N and D69.97N mutants can best be explained by three active 
receptor conformations, at least two of which are strongly agonist-dependent. The loss 
of high affinity guanine nucleotide-sensitive agonist binding was correlated with the 
loss of adenylyl cyclase inhibition and phospholipase C stimulation by acetylcholine, 
carbachol, and pilocarpine but not by oxotremorine M. Oxotremorine M appeared to 130 
stabilize an active receptor conformation in the mutants that was different from the 
conformation associated with high affinity guanine nucleotide-sensitive agonist binding 
in wild-type. 
An alternative explanation is that the active receptor conformations are 
essentially the same qualitatively but are diminished quantitatively between the wild-
type and the mutant. This is possible but cannot easily explain the relatively small 
change in the extent of phospholipase C stimulation observed in D69N-containing 
mutants. Since the EC50s for adenylyl cyclase inhibition and phospholipase C 
stimulation were different in wild-type they could have resulted from different G 
proteins that have different affinities for the active receptor conformation. A decrease 
in this affinity would affect all G proteins interacting with this receptor conformation. 
A dramatic loss in receptorG protein affinity, observed as the loss of high affinity 
guanine nucleotide-sensitive agonist binding, would be expected to have a dramatic 
effect on EC50 for adenylyl cyclase inhibition, a smaller effect on the EC50 for 
phospholipase C stimulation, and a dramatic effect on the extent of phospholipase C 
stimulation. In the D69N mutant the EC50 for phospholipase C stimulation was 
unchanged. If there were two G proteins with different receptor affinities responsible 
for these effects, then phospholipase C stimulation (the lower affinity effect) should not 
have been observable in a mutant that results in a dramatic decrease in receptorG 
protein affinity (29). A second alternative involves a single G protein (or a repertoire of 
G proteins that act similarly) stimulating both the inhibition of adenylyl cyclase and the 
stimulation of phospholipase C. Pertussis toxin-sensitive stimulation of phospholipase 
Cfr is thought to occur via G protein fry subunits and to require a relatively high 
concentration (54) while adenylyl cyclase inhibition occurs principally via the ai 
subunit. As in the first alternative the EC50s for both effects should have been shifted 
and phospholipase C stimulation should have been the more difficult effect to observe. 131 
Phospholipase C stimulation was observable and its EC50 was not significantly shifted 
in the D69N mutant. 
An agonist-specific active receptor conformation best explains the adenylyl 
cyclase stimulation observed in the D69N mutant, which occurs via a pertussis toxin-
insensitive G protein, unlike the other effects. This effect in wild-type was the weakest 
and was observed only at high receptor levels. In the D69N mutant, which expressed 
receptor at very high levels, adenylyl cyclase stimulation was observed only with 
acetylcholine and carbachol. This stimulation was unlikely to have occurred via the 
same active receptor conformation that was responsible for high affinity guanine 
nucleotide-sensitive agonist binding because that would also result in adenylyl cyclase 
inhibition and phospholipase C stimulation, which were not observed with these 
agonists. It was also unlikely to occur via the second active receptor conformation, 
which oxotremorine M stabilizes, because acetylcholine and carbachol do not stabilize 
a similar conformation. There is little evidence that these additional agonist-specific 
active receptor conformations exist and are significant routes to receptor activation in 
the wild-type receptor; however, they are present and significant in the D69N mutant. 
The mutagenesis of the D69 homologous residues in the rhodopsin-like family 
of G protein-coupled receptors has typically resulted in reduced agonist affinity, 
especially the guanine nucleotide-sensitive component of agonist binding, and 
functional activity that was either eliminated or reduced (6, 32, 34-37, 55-61). The 
D69N mutant exhibits an agonist-specific change in the specificity of functional 
activity, a characteristic shared with the a2-adrenergic receptor. The mutation in the 
a2-adrenergic receptor resulted in the elimination of the wild-type ability to stimulate 
inwardly-rectifying potassium currents but the inhibition of adenylyl cyclase and 
voltage-gated calcium currents were relatively unaffected (57). The m2 muscarinic 
receptor and the a2-adrenergic receptor share a similarity that most effects are 132 
mediated by pertussis toxin-sensitive G proteins. The change in specificity observed in 
the m2 muscarinic receptor and in the a2-adrenergic receptor suggest that this 
homologous aspartate plays an additional role in G protein specificity that may be 
limited to G protein-coupled receptors that mediate their effects predominantly through 
pertussis toxin-sensitive G proteins. 
The role of D97 
This conserved residue is thought to contribute moderately to the stabilization 
of the ligand-bound receptor state. When similarly mutated in the 132-adrenergic 
receptor (EA) there was no effect on antagonist or agonist affinity but in the ml 
muscarinic receptor (D -*N) these effects were greater (32). The effects reported here 
for this conserved site in the m2 muscarinic receptor are similar to the ml subtype 
results. The m2 muscarinic receptor is better suited than the ml subtype to evaluate 
effects on agonist binding because agonist affinities are well separated and clearly 
defined in competition binding assays. 
The results of functional coupling assays (Tables 4.4 and 4.5) agree with 
decreased binding affinity (Table 4.1) for agonists for the D97N mutant. The agonist 
binding affinities to the guanine nucleotide-sensitive high affinity site (KH values, 
Table 4.1) were decreased by an average 11-fold for the four agonists between the 
wild-type and D97N and by an average 10-fold for the free receptor (KM values). D97 
appeared to contribute approximately the same amount of binding energy for agonist to 
the G protein-coupled state as it does to the free receptor. The results indicate that the 
role of D97 is limited to providing slightly more than approximately 1 kcal/mole of 
binding energy on average to the binding of agonists and slightly less to the binding of 
antagonists (Table 4.2). Located at the extracellular end of the putative transmembrane 
ligand binding domain, D97 is well positioned to serve as a secondary anionic site in a 133 
sequential amine ligand binding mechanism. Binding data support such a role for this 
residue. 
Thermal inactivation 
Results from thermal inactivation studies (Table 4.3) suggest that the D69, D97, 
and D103 are not critical for structural stability of the unliganded state. QNB stabilized 
the wild-type and mutant receptors that contained aspartate at position 103 to thermal 
inactivation; in D103N-containing mutants the stabilizing effect was lost. The simplest 
explanation is that D103 has a role in protein stability distinct from its role in ligand 
binding. Alternatively, QNB might bind the receptor in an additional or alternative 
manner. The possibility of an additional site was examined. Equilibrium binding 
experiments on the wild-type receptor membranes conducted at sufficiently high QNB 
concentrations to observe a low affinity site similar to the one observed in the 
D69.103N and D97.103N mutants failed identify such a site (data not shown). This 
negative result does not exclude the possibility of an additional site because the site 
may only exist in D103N-containing mutants. The significance of the QNB-dependent 
thermal stability to agonist-bound receptor states in unclear. Far-UV CD spectra of 
detergent-solubilized purified m2 muscarinic receptor were indistinguishable in the 
unliganded versus the agonist-bound states; however, the QNB-bound state contained 
4% less a-helix and 4% more a-sheet than the unliganded state (26). Negative 
antagonism observed in adenylyl cyclase assays was interpreted as the binding of QNB 
to give a receptor state that is different from the unliganded and the agonist-bound 
states (29). 
Effects of double mutants 
Results from the D69.97N double mutant indicate that the effects of D69N and 
D97N on binding equilibria were approximately additive (Table 4.2) (62). The 134 
interpretation of the double asparagine mutants between D69 and D103 and between 
D97 and D103 is complicated by the lack of any more than an estimate of QNB affinity 
to the D103N single mutant. The data are consistent with additivity or superadditivity, 
where the effect of the double mutant is greater than the sum of the individual mutants, 
between D69N and D103N and/or with additivity or subadditivity, where the effect of 
the double mutant is less than the sum of the individual mutants, between D97N and 
D103N. Complicating any interpretation are the effects that these mutants had on 
protein structure and stability. Thermal inactivation studies suggest that these 
mutational effects on protein stability were small, but even a small effect may have a 
large effect on ligand binding. 
An interesting question is whether D97 and D103, positioned close to each 
other in helix 3, are capable of cooperative binding of ligand or have separate roles. If 
they cooperate in the binding of ligand the expected outcome of the double mutant is a 
synergistically deleterious (superadditive) effect on ligand binding. Since D97.103N 
binds ligands with higher affinity than D69.103N a lack of cooperativity or separate 
roles for D97 and D103 is the simplest explanation. 
Another interaction between D97 and D103, unrelated to ligand binding 
equilibrium, was the effect of D97N and D103N on the expression of antagonist 
binding sites. As measured by antagonist binding, D97N was more poorly expressed 
than wild-type and D103N was very poorly expressed but the double mutant D97.103N 
was expressed approximately as well as D97N. It is not known if this reduced cellular 
expression was due to reduced protein translation, incorrect processing, or improper 
folding to a conformation capable of binding antagonist. Evidence that poor antagonist-
detectable cellular expression of mutant muscarinic receptors was due at least partly to 
incorrect protein folding was demonstrated with helix 3 mutants of the ml muscarinic 
receptor. Immunocytochemistry identified cell surface expression that was in great 135 
excess of the antagonist detectable mutant receptor; the small population of receptor 
that bound antagonist did so with wild-type affinity (63). 
In conclusion, we find that the conserved aspartate in the middle of helix 3 
(D103) plays a significant role in receptor activation in addition to and apart from its 
role in ligand binding, a role not generally shared among the amine-binding class of G 
protein-coupled receptors. In addition to its role in the formation of active receptor 
conformation(s) the conserved aspartate in helix 2 (D69) plays a related role of 
contributing to the specificity of functional activity. The effects of the asparagine 
mutations of residues D69 and D97 are approximately additive in the doubly mutated 
receptor. However, D103N is not additive with D69N and/or D97N. Finally, D97 
appears to contribute to ligand binding by providing a secondary anionic site, a role 
that does not appear to be cooperative with the nearby D103. 
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Chapter 5 
Summary 
When the m2 muscarinic receptor was exogenously expressed in Chinese 
hamster ovary cells assays of its functional activity were not reproducible. In assays of 
forskolin-stimulated adenylyl cyclase inhibition the concentration of agonist required to 
achieve a half-maximal effect (EC50) varied while the EC50 values from assays of 
phospholipase C stimulation were invariant. The source of this variability was the 
expression level of the receptor; the EC50 for adenylyl cyclase inhibition decreased with 
increasing receptor level. Further investigation led to additional observations. The 
maximal response of phospholipase C stimulation increased with receptor level while the 
maximal response of adenylyl cyclase inhibition assays did not, except for cells treated 
with pilocarpine. In adenylyl cyclase inhibition assays antagonist controls sometimes 
appeared to more than reverse the agonist effects. Further experiments showed that 
antagonists appeared to stimulate adenylyl cyclase where they should have had no effect. 
At high agonist concentrations the adenylyl cyclase inhibition was reversed, apparently 
stimulated with an EC50 that decreased and a maximal effect that increased with receptor 
level. This G protein-mediated effect was unlike all other m2 muscarinic receptor effects 
in being insensitive to pertussis toxin, suggesting that the G protein involved was not Gi 
or Go. The best explanation for this effect is a 137 subunit from Gz, a member of the Gvo 
family of G proteins that is not sensitive to pertussis toxin. It should be noted that this 
effect requires both a very high concentration of agonist and high-level receptor 
expression; it is not likely to be physiologically relevant. 
Before we could analyze the effects of site-directed mutants we needed to 
understand the effects that wild-type expression levels had on functional activity. The 
model that resulted not only provided an explanation for these observations but also 143 
provided additional insight into the fundamental problem of the relationship between 
agonist binding and G protein-coupled receptor activity. The ternary complex model was 
expanded to include explicit activation and inactivation steps originating from the 
agonistreceptorG protein ternary and the receptorG protein binary complexes. 
Functional activity was modeled to be proportional to the steady-state concentration of 
activated G protein. Muscarinic effects seen in phospholipase C stimulation and adenylyl 
cyclase inhibition assays were explained by muscarinic receptors coupling to these 
effects via different G proteins that bound the receptor with different affinities. The 
model explained the partial agonism observed with pilocarpine that disappeared at high 
receptor level as originating from the lower ratio of high to low agonist affinities 
compared with the other agonists and the lower absolute affinity of pilocarpine for the G 
protein-coupled receptor conformation. Negative antagonism was explained by the 
reduction in basal activity originating from the receptorG protein binary complex by the 
binding of antagonist to the inactive receptor conformation. 
At the time of the preparation of Chapter 2 for publication the significance of fry 
effects in G protein signaling was uncertain. It is now throught to be a significant route 
of G protein signaling. Py was first reported to stimulate the cardiac inwardly-rectifying 
potassium channels in 1987 (1). Subsequent reports both confirmed (2) and contradicted 
(3) that conclusion. Until it was resolved in 1994 (4, 5) in favor of 13y, it was not known 
if an au° or a Dy subunit or both were responsible. In adenylyl cyclases the role of Pry 
subunits appears to be secondary to the stimulatory effect of as and the inhibitory effect 
of a1. Of the nine adenylyl cyclase subtypes 13y inhibits only Type I while the 07 
stimulation of Types II and IV occurs only synergistically with as (6). Phospholipase C 
stimulation was known to proceed via both pertussis toxin-sensitive and insensitive 
routes. The pertussis toxin-insensitive route was worked out first and found to proceed 
via the a subunits (7-9) of a new family of G proteins (later identified as the Gqin 144 
family). Initial reports identified ao as the specific G protein subunit mediating the 
pertussis toxin-sensitive route of stimulation (10, 11). Reports of the involvement of [37 
soon followed (12-16) but it was not clear at first whether its effects were secondary to 
an a subunit effect as was seen for adenylyl cyclase stimulation. The requirement for 
high concentration of 137 and pertussis toxin sensitivity led to the conclusion that the 
high-abundance Gvo family is the only physiologically relevant source of 137 subunits 
(17). 
In Chapter 2 we suggested that multiple G proteins interacting with the receptor 
with different affinities could explain the dissimilar effects observed in assays of 
adenylyl cyclase inhibition and phospholipase C stimulation. The more likely explanation 
for these effects now appears to be bifurcating signaling via a and 13y subunits. A single 
G protein or a repertoire of G proteins with similar affinities could also produce the 
observed effects if the active subunits bind effectors with different affinities. Originally 
we modeled effector activity to be proportional to the steady-state concentration of 
activated G protein; the inclusion of explicit subunit affinities adds to the complexity of 
the model (Figure 5.1). 
The model (Scheme 2.2 and the scheme in Figure 5.1) describes partial agonists 
as compounds with a relatively low ratio of binding affinities for the active and inactive 
receptor conformations compared to other compounds. Whether partial agonism is 
observed or not depends the ratio of agonist affinities to G protein affinities and the 
concentrations of receptor and G protein. The relatively low absolute and low ratio of 
high to low affinity explained the observation of pilocarpine partial agonism that 
disappeared at high receptor levels. This is the only possible explanation of partial 
agonism if different agonists bind receptor to promote the same active receptor 
conformation, and results with the wild-type receptor can be adequately explained by a 
single active receptor conformation. Results with the D69N mutant (Chapter 4) cannot 145 
Figure 5.1. Ternary complex model with kinetic pathways toward G protein 
activation and inactivation. A is agonist, G is the GDP-bound G protein heterotrimer, 
R is the free receptor, AR is the agonist bound receptor, RG is the G protein bound 
receptor, and ARG is the agonistG proteinreceptor ternary complex. E1 and E2 are 
effectors that are bifurcately activated by oc-GTP and r3y subunits. GTP hydrolysis on 
the a subunit is shown to occur via two routes; the secondary effector-accelerated route 
has been observed in some systems. 146 
be easily explained with fewer than three active receptor conformational states, at least 
two of which are agonist-specific, but there is no evidence that these two additional 
conformations are present and significant in the wild-type receptor. Multiple active 
receptor conformations that are differentially stabilized by agonists are the basis of an 
alternative explanation of partial agonism that is based on conformational selectivity. 
A second argument for the model in Figure 5.1 is that it is capable of explaining 
the adenylyl cyclase stimulation observed at high agonist and receptor levels. In Chapter 
2 we pointed out that this effect was inconsistent with the model as then presented. 
Modeling activity as proportional to the steady-state concentration of activated G protein 
imposed a restriction that EC50 for an effect could not exceed the dissociation constant of 
agonist for the free receptor. A 137 effect, typically requiring a high concentration of this 
subunit, can have an EC50 greater than the agonist dissociation constant. The observation 
of adenylyl cyclase stimulation is consistent with the model in Figure 5.1. Also 
unexplained in Chapter 2 was the identity of the KL site observed in agonist binding 
assays. It was thought to be either modified or aggregated receptor but since its 
concentration did not change in the presence of guanine nucleotides, it did not appear to 
be receptor state involved in G protein signaling. Results from Chapter 4 indicate that 
guanine nucleotide sensitivity is not a requirement of functional activity, at least with 
some receptor conformational states. There no longer is any reason to conclude that the 
KL site is not capable of interacting with G proteins. 
The ability of the model to relate changes in agonist affinities of the active and 
inactive receptor conformation to functional activity was exploited to explain the results 
of the site-directed mutant Y403F, a conserved residue in the sixth transmembrane helix, 
and resolved apparently conflicting results of the homologous mutation in the m3 
muscarinic receptor. In the m3 subtype the mutation resulted in decreased agonist 
affinity and decreased functional activity and led to the conclusion that the residue was 147 
involved in agonist binding and had a separate role in G protein activation (18). In the 
m2 subtype agonist affinities were more affected but functional activity was wild-type­
like except for pilocarpine where the functional activity was reduced in one assay and 
eliminated in another. The effects observed in both subtypes were explained by the 
decreased ratio of high affinity to low affinity agonist equilibrium constants for 
pilocarpine and an increased ratio for other agonists in the m2 subtype while the ratio 
decreased for comparable agonists in the m3 subtype. 
Results from studies of muscarinic receptors and other rhodopsin-like family G 
protein-coupled receptors led to the identification of certain helices, conserved sites, and 
specific residues as being involved in receptor function, agonist binding, or both, but less 
is known about how these might interact. Helix 3 appears to have multiple roles. At the 
extracellular end it is involved in agonist binding; and its movement relative to helix 6, 
also a site of agonist binding, might be part of an activating conformational change. In 
muscarinic receptors there are two aspartates in the middle and extracellular end of helix 
3 that affect agonist binding, one of these dramatically. Rhodopsin projection structures 
(19, 20) suggest a close proximity of helices 2 and 3, and two highly conserved motifs 
that could conceivably interact are found at the intracellular ends. The conserved aspartate 
in helix 2, the most conserved residue in helix 2 and part of the motif, is critical to 
function and its relationship to agonist binding is most likely to be indirect. We produced 
site-directed asparagine mutants of the three conserved aspartates in helices 2 and 3 and 
produced double mutants of each of these for the purpose of identifying and 
characterizing potential nonadditive interactions between these sites. 
The results indicate that between D69 ( in helix 2) and D97 (near the extracellular 
end of helix 3) both binding and functional activity were approximately additive. 
However, results with the D103 site (in the middle of helix 3) indicated that this site was 148 
nonadditive. The results are difficult to interpret because the single D103N mutation was 
not expressed well enough to be characterized. 
A synergistic effect was observed between the D97N and D103N as the double 
mutant D97.103N was expressed as well as the D97N, while individually these mutants 
had a negative effect on the expression of antagonist binding sites. The conclusion from 
these results was that the absence of a carboxylate-bearing functional group at position 
103 introduced a large bather to proper protein folding or processing. This barrier was 
significantly reduced in the absence of a second carboxylate at position 97 but the 
reasons for this are unclear. 
D97 and D103 positioned close to each other in the upper portion of helix 3 
individually contribute to the binding of ligand. They could contribute synergistically to 
the same binding step or to separate binding steps in a sequential binding mechanism. If 
both residues contributed to the same binding step then their joint removal would be 
expected to have a synergistically deleterious effect on ligand binding. The D97.103N 
double mutant bound ligands better than the D69.103N double mutant. The conclusion 
most consistent with this result was that these residues contribute to separate binding 
steps. 
Although the D103N mutation was not available for characterization, its effects 
could be evaluated by considering the results from the D97N single and the D97.103N 
double mutants. The D97N mutation reduced apparent agonist binding energies 
modestly and its effects in assays of functional activity were consistent with reduced 
agonist affinity. The D97.103N mutant reduced ligand affinities dramatically, eliminated 
high affinity guanine nucleotide-sensitive agonist binding, and eliminated functional 
activity completely at receptor expression levels at which wild-type-like functional 
activity was observed in D97N. The typical result from G protein-coupled receptors that 
conserve this residue is that ligand binding is dramatically reduced but functional activity 149 
is preserved, at least partially, and consistent with the reduced agonist affinity. In 
muscarinic receptors this residue appears to have a role in receptor function that is 
additional to and distinct from the typical ligand-binding role of this conserved residue. 
Results with D69N, the conserved helix 2 aspartate, were also atypical of results 
from other members of the rhodopsin-like family of G protein-coupled receptors. 
Homologous mutations typically eliminate or significantly reduce high affinity guanine 
nucleotide-sensitive agonist binding and functional activity. This was also observed in 
D69N but the activity that remained was agonist specific suggesting the existence of 
active conformations of the receptor that can be differentially stabilized by agonists. 
There is little direct evidence that the additional two active conformations exist and are 
significant to wild-type receptor function. The simplest explanation is that the mutation 
resulted in the elimination of the predominant active receptor conformation that is 
stabilized all agonists. The two additional active conformations, one that is stabilized in 
the mutant only by oxotremorine M and the other that is stabilized by acetylcholine and 
carbachol but not oxotremorine M, exist in the wild-type but are not significant to overall 
function. 
We gained insight into the roles of these conserved aspartates but were unable to 
discern from their combined effects a significant nonadditive effect between helices 2 
and 3. The simplest explanation is that no significant nonadditive relationship exits 
between these helices. This conclusion would require more experiments than the few that 
have been completed. Asparagine mutagenesis may have been too large a change in 
residues 69 and 103. Glutamate mutations at these sites might be more productive. 
Residue 103 is a particular problem because mutations at this site are not well tolerated. 
D103E mutants have been reported transiently expressed in COS cells (21, 22); however 150 
stable expression has been elusive.1 Since this mutation preserved, albeit dramatically 
altered, high affinity acetylcholine and carbachol binding (but interestingly oxotremorine 
M and pilocarpine high affinity binding was eliminated) it might be more sensitive to an 
alteration in helix 2 (21). D69E has the potential to alter without eliminating guanine 
nucleotide-sensitive agonist binding but this has yet to be demonstrated. D69E or some 
other mutation near it that alters but does not eliminate guanine nucleotide-sensitive 
agonist binding might likewise be more sensitive to an alteration in helix 3. 
Several diseases are associated with impaired G protein-coupled receptor 
signaling; for example, 0-adrenergic receptor in heart failure, dopamine receptors in 
Parkinson's disease, and muscarinic receptors in Alzheimer's disease. Agonist-based 
therapeutic approaches are either the current art or are contemplated. The realization that 
receptor level has an effect on functional activity is not novel. How receptor levels might 
affect the nature of receptor function, specifically altering or not altering maximal effect 
and affecting or not affecting the EC50, was poorly understood. The ability to relate 
absolute and relative agonist affinities and G protein affinities quantitatively resulted in 
new insight into the mechanism of G protein-receptor-coupled effects. The development 
of subtype-specific pharmaceuticals is critical to effective treatments that have a 
minimum of side effects. The poor tolerance of muscarinic agonists is a major 
impediment to an effective treatment Alzheimer's disease. Recent clinical studies with 
m 1 (23) and m 1 and m4 (24) selective agonists suggest that this approach has promise. 
The development of better treatments and a more sophisticated understanding of the 
disease may be aided by a more detailed understanding of the mechanism of receptor 
function. 
1D103E and D103C were not expressed well in stably transfected CHO cells, D. J. Broderick and M. 
I. Schimerlik, unpublished data. 151 
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Direct ligand binding 
Scheme A.1 describes the equilibrium binding of radiolabeled ligand (L) to 
receptor (R) to form specifically bound receptor (RL). The dissociation constant (K) is 
described by Equation A.1. Nonspecifically bound ligand is modeled to be proportional 
to the free ligand concentration and the proportionality constant is N. 
R + L  RL
 
Scheme A.1
 
K  _,[1?][L]  [A.1] 
[RL]
 
The mass balance equations are,
 
[Ro] = [R] + [RL]  [A.2] 
[Lc] = [L] + [RL] + N[L]  [A.3] 
where [Ro] and [Lo] are the total receptor and ligand concentrations and N[L] is the 
nonspecifically bound ligand. 
A relationship for total bound ligand as a function of free ligand concentration is 
the sum of specific, [RL], and nonspecifically, N[L], bound ligand. 
[RON 
N[L]  [A.4] 
IC-F[L] 
A relationship for total bound ligand as a function of total ligand concentration is 
likewise the sum of specific, [RL], and nonspecifically, N[L], bound ligand. 
([Re]  [R0([1-0]  [RL])  [A.5] [RL]  K(N + 1) 
Solving the quadratic in [RL] gives, 
2[Ro ][4]  [A.6] [RL] 
K(N + 1) + [Ro] +  [L0] + V(K(N + 1) + [RO] +[L° D2  4[Ro][1,0] 175 
Nonspecifically bound ligand as a function of total ligand concentration is found by 
rearranging Equation A.3, 
N([4] [An)
N[L] =  [A.7]
N +1 
Competition Equilibrium Binding 
Scheme A.2 describes the equilibrium binding of unlabeled ligand (A) to n 
noninteracting classes of sites (R1) that bind labeled ligand (L) with the same affinity to 
form specifically bound receptor (RiL). 
-A  +L DRA 
KJ  R 
i=1 
Scheme A.2 
K =[Ri][L]  [A.8] 
K  [A.9] [RIA] 
The mass balance equations are, 
[Re] =  +[R,L,]+[R,A])  [A.10] 
[] = [L] + N[L1+±jR,L1  [A.11] i
[A.12] [Ad= [A]  +NA[A] +i[RA] 
1=1 
where [R0], [Lo ], and [Ad are total receptor, labeled ligand, and unlabeled ligand, 
respectively, K is the dissociation constant of the L-bound complex, (RL), and K. is the 
dissociation constant of the A-bound complex, AA. Nonspecific binding of the labeled 
ligand is modeled to be proportional to its free ligand concentration, [L], and the 176 
proportionality constant is N. In the general case nonspecific binding of the unlabeled 
ligand is modeled to be proportional to its free ligand concentration, [A], and the 
proportionality constant is NA. The concentration of specifically bound receptor, for A 
bound to a single site, is described by, 
[RL]) [Ro]([L0 =  [A.13] 
,x(i+ [Lo] -n [A0 [R 
where  a=K(N+1)  [A.14] 
and  = K, (NA +1)  [A.15] 
Equation A.13 can be rearranged to a third-order polynomial, 
a[RI]3 + b[RL]2 + c[RL] + d = 0  [A.161
 
where  a = /3i  a  [A.17]
 
b =  + 44] + [Ro]  [Ad) 16,([Ro] + 2[4]) afli  [A.18]
 
[A.19] c = c0-0 X[Ao] + A AO ALL0141+ 2[Ro]) 
d =  f3[Lo]2[Rol  [A.20] 
The specifically bound concentration of receptor is obtained efficiently by solving 
Equation A.16 via Newton's Method. An explicit solution can be obtained with the cubic 
equation but the solution is difficult to calculate reliably under certain conditions. 
Under typical conditions, [A0] --- [A] since no displacement occurs until 
[A] > [Ro], a simplified solution can be derived. The specifically bound concentration for 
A bound to n sites is described by, 
[RL] = [Ro ILO] [RLOL  [A.21] [41 177 
where  = K(N +41+1  [A.22]
K 
and F, is the fraction of total receptor that binds A with the dissociation constant Ki. 
Equation A.21 has a quadratic solution for n = 1, 
2[R0][4] [RL] =  [A.23] 
al +[L0] +[R0]+ V(cci + [4] + [Ro])2  4[Ro][4] 
Equation A.21 has a solution in the root of a third-order polynomial for n = 2, 
[RL]3 + a[RL]2 + b[RL] + c = 0  [A.24]
 
where  a =  a2  2[4] -[R,3]  [A.25]
 
b = ala2+[4](al+ a2 + [4] + 2[R,3])+[Rja2F, + a1F2)  [A.26]
 
c = -[4][R4a2F1 +a,F2+[4])  [A.27] 
Equation A.21 has a solution in the root of a fourth-order polynomial for n = 3, 
[RL]4 + a[RL]3 + b[RL]2 + c[RL] + d = 0  [A.28] 
where  a =  a2  a3  3[4] -[R,3]  [A.29] 
b= ala2+a,a3 + a,a3+ [4](2(a, + a2+a,)+3([4]+[Ro])) 
[A.30] 
+[Ro](Fi(a2 + a3)+ F2(a, + a3)+ F3(al + a2)) 
c = -a,a2a3-[Ro](a2a3F, + oca3F2+a,a2F3) 
-[4](a,a2+ a,a3+ a2a3 + [4](ai+ a2 + a3 +[i  [A.311 
-2[4][Rd(F,(a2+ a3) + F2(a1 + a3) + F3 (a, + a2)) 
d = [4][Ro](a2a3F1 +a,a3F2+a,a2F3)+[4]3[Ro] 
[A.32] 
+[4]2[0F,(a2+a3)+ F2 (a, + a3) + F3(a,+ a2)) 178 
The total bound ligand is the sum of specifically, UM, and nonspecifically, 
NG Lo]  [RI]) 
, bound ligand.
N +1 